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Abstract
Neuroinflammation plays a central role in a variety of neurological diseases, including stroke, 
multiple sclerosis, Alzheimer’s disease, and malignant CNS neoplasms, among many other. 
Different cell types and molecular mediators participate in a cascade of events in the brain that is 
ultimately aimed at control, regeneration and repair, but leads to damage of brain tissue under 
pathological conditions. Non-invasive molecular imaging of key players in the inflammation 
cascade holds promise for identification and quantification of the disease process before it is too 
late for effective therapeutic intervention. In this review, we focus on molecular imaging 
techniques that target inflammatory cells and molecules that are of interest in neuroinflammation, 
especially those with high translational potential. Over the past decade, a plethora of molecular 
imaging agents have been developed and tested in animal models of (neuro)inflammation, and a 
few have been translated from bench to bedside. The most promising imaging techniques to 
visualize neuroinflammation include MRI, positron emission tomography (PET), single photon 
emission computed tomography (SPECT), and optical imaging methods. These techniques enable 
us to image adhesion molecules to visualize endothelial cell activation, assess leukocyte functions 
such as oxidative stress, granule release, and phagocytosis, and label a variety of inflammatory 
cells for cell tracking experiments. In addition, several cell types and their activation can be 
specifically targeted in vivo, and consequences of neuroinflammation such as neuronal death and 
demyelination can be quantified. As we continue to make progress in utilizing molecular imaging 
technology to study and understand neuroinflammation, increasing efforts and investment should 
be made to bring more of these novel imaging agents from the “bench to bedside.”
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Introduction
Neuroinflammation plays a central role in a variety of neurological diseases, including 
cerebrovascular disease (e.g., stroke), demyelinating diseases (e.g., multiple sclerosis, MS), 
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tneurodegeneration (e.g., Alzheimer’s disease), and malignant CNS neoplasms (e.g., 
glioblastoma multiforme), among many others [1–6]. Depending on the specific condition, 
different cell types and molecular mediators (e.g., cytokines, chemokines) participate in a 
cascade of events in the brain that is ultimately aimed at control, regeneration and repair, but 
leads to damage of brain tissue under pathological conditions [2,7,8]. Activation of the 
resident leukocyte in the brain, the microglia, presents one of the hallmarks of 
neuroinflammation, which is often accompanied by blood-brain barrier (BBB) breakdown, 
cytokine and chemokine release, as well as blood-borne leukocyte infiltration. Damage to 
neurons and myelin sheaths can be caused by myeloid cells through oxidative stress, 
phagocytosis, and proteases, and by lymphocytes through antibody-dependent cell-mediated 
cytotoxicity or cytolytic granule release [9].
Therefore, neuroinflammation is a highly relevant diagnostic and therapeutic target, but 
several characteristics of the brain make both goals more difficult than at other sites in the 
body. First, the brain has the BBB, which prevents most molecules from entering the brain. 
Thus, imaging probe and drug design needs to bypass this challenge. Second, cranial bones 
complicate direct access to the brain for diagnostic (e.g., biopsies for tissue sampling) or 
therapeutic (e.g., surgery) interventions, and even distorts signal of certain (e.g., optical) 
imaging techniques. Lastly, the brain has very limited regeneration capacity, which makes 
secondary and tertiary prevention more difficult, so early diagnosis is of utmost importance.
Although neuroinflammatory diseases have been visualized with a variety of imaging 
techniques and agents, the majority of imaging in current clinical practice is done with 
methods not specifically targeted at molecular mediators of the immune system. For 
example, gadolinium-enhanced magnetic resonance (MR) imaging detects BBB breakdown 
but is not specifically targeted at the molecules and cells that facilitate this process. It is 
therefore not surprising that BBB breakdown on MR imaging and inflammation do not 
always correlate [10].
Molecular imaging techniques that non-invasively visualize specific targets of the 
inflammation cascade using specific and sensitive probes could be powerful tools to 
evaluate neuroinflammation in the clinical and pre-clinical settings. This could allow for 
more sensitive and earlier detection as well as for monitoring disease progression and 
response of patients to therapeutic interventions. Over the past decade, a plethora of 
molecular imaging agents have been developed and tested in animal models of 
neuroinflammation, and a few have been translated from bench to bedside. The most 
promising imaging techniques to visualize neuroinflammation include MRI, positron 
emission tomography (PET), single photon emission computed tomography (SPECT), and 
optical imaging methods. In this review, we focus on molecular imaging techniques that 
target inflammatory cells and molecules that are of interest in neuroinflammation, especially 
those with high translational potential. Figure 1 illustrates the targets and the imaging agents 
for neuroinflammation, while Figure 2 shows the targets and agents for damage caused by 
neuroinflammation.
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Migration of blood-borne leukocytes through the endothelium (and the BBB) is a multi-step 
process consisting of chemoattraction, adhesion, and transmigration [11,12]. While 
chemoattraction is mediated via various cytokines that often have redundant functions and 
cell targets, adhesion is mediated through interaction of endothelial cell selectins (e.g., P- or 
E-selectin), VCAM-1, or ICAM-1 with leukocyte integrins (e.g., VLA-4, LFA-1, Cd11b, 
etc.). Further interaction with adhesion molecules such as PECAM-1 facilitates 
extravasation into the subendothelial space, where exposure to the local cytokine 
microenvironment directs leukocytes further towards their target [12]. Drugs that target 
leukocyte adhesion molecules can be highly efficient, exemplified by the monoclonal 
antibody natalizumab, which binds α4β1 integrin and is an established drug for MS [13].
Molecular imaging probes to detect adhesion molecules must have several characteristics to 
be successful: First, their physical size has to be big enough (generally >500 kDa) to prevent 
non-specific leakage through a compromised BBB. Second, good binding capacity under 
conditions of high shear stress in vessels is important. Finally, high sensitivity and 
specificity is key to detect subtle changes in the expression of these molecules in 
inflammation.
Vascular cell adhesion molecule-1 (VCAM-1 or CD106)
VCAM-1 is an adhesion protein of the immunoglobulin superfamily expressed on 
endothelial cells. It is highly upregulated following stimulation with cytokines, and 
facilitates adhesion of different leukocyte populations. In a proof-of-concept study, McAteer 
et al. [14] conjugated an anti-VCAM-1 antibody to 1 μm sized micron particles of iron oxide 
(MPIO), further referred to as VCAM1-MPIO. In a mouse endothelial cell line stimulated 
with TNF to upregulate VCAM-1 expression, VCAM1-MPIO retention was detected. In 
vivo, after intracerebral injection of IL-1β into the striatum, focal hypointensities on T2 
weighted MR imaging were detected consistent with accumulation of VCAM1-MPIO 
(Figure 3A). Specificity of this approach was demonstrated by injecting an isotype IgG 
antibody conjugated to MPIO (IgG-MPIO) and pre-treatment with an anti-VCAM-1 
antibody to block binding of VCAM1-MPIO. In both experiments, no significant T2 signal 
alteration was detectable [14]. Applying the same probe to a mouse model of brain 
metastases using 4T1 or MDA231BR cell injections, VCAM1-MPIO allowed for earlier 
detection of metastases, and the authors concluded this might translate to improved detection 
of metastases [15]. In cerebral ischemia using the middle cerebral artery occlusion (MCAO) 
model, a greater area of VCAM-1 expression was detected compared to the DWI 
hyperintense area, suggesting that hypoperfused brain regions at risk for infarction 
upregulate VCAM-1 [16]. In experimental autoimmune encephalomyelitis (EAE), a mouse 
model of MS, VCAM1-MPIO allowed for detection of subclinical disease at a stage when 
lesions were undetectable by DTPA-Gd enhanced MR imaging. In symptomatic mice, 
VCAM1-MPIO detected all lesions visible with DTPA-Gd plus additional lesions 
corresponding to areas of leukocyte infiltration on histology [17]. Finally, utilizing the 
pilocarpin model of seizure, focal hypointensities were found in the periventricular organs, 
the hippocampus, and cerebral cortex with VCAM1-MPIO [18].
Pulli and Chen Page 3
J Clin Cell Immunol. Author manuscript; available in PMC 2014 December 16.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tWhile these studies provide proof-of-principle evidence that molecular MR imaging 
targeting endothelial VCAM-1 expression in vivo is feasible, a major concern is sensitivity 
in diseases with only subtle inflammation, such as dementia. Montagne et al. [19] addressed 
this issue by using a different anti-VCAM-1 antibody clone. While McAteer et al. used M/
K-2, Montagne et al. evaluated both M/K-2 and A(429), and found a greater than 250% 
signal increase with A(429). With this optimized agent, they were able to detect not only 
inflammation in EAE and after intracerebral TNF injection (Figure 3B–3C), but also in the 
unilateral common carotid artery occlusion model of vascular dementia, the APPPS1 model 
of Alzheimer disease, as well as subtle neuroinflammation after systemic challenges with 
LPS, ethanol, or glucose [19]. Extending their findings to stroke, the same group found 
extended VCAM-1 upregulation with permanent but not transient MCAO in peri-infarct 
areas, suggesting an inflammatory penumbra that subsequently infarcts [20].
Another approach to image VCAM-1 not yet applied to neuroinflammation includes affinity 
peptide ligands for MRI or PET/CT. In one study, phage display derived peptides were 
screened in vitro through a murine endothelial cell line to identify a candidate peptide that is 
internalized specifically via VCAM-1. This peptide was conjugated to CLIO-Cy5.5 for dual 
MR and fluorescence imaging of atherosclerosis [21]. In vivo phage display later identified a 
linear peptide affinity ligand named VINP-28, further refining this approach. VINP-28 is 
homologous to VLA-4, which is a known ligand for VCAM-1. After conjugation to CLIO-
Cy5.5, affinity was found to be 20 times higher compared to the former approach, and dual 
modality imaging was performed with MR and fluorescence imaging in atherosclerosis [22]. 
A similar affinity peptide ligand was also labeled with 18F for PET/CT imaging, and 
successfully tested in mouse models of atherosclerosis, myocardial infarction, and cardiac 
transplant rejection [23].
E-/P-selectin (CD62)
E- and P-selectins (or CD62E/P) are adhesion molecules expressed on endothelial cells, and 
they are also upregulated in the presence of inflammation. A binding partner for these 
molecules is sialyl Lewisx (sLex), which is expressed on leukocytes. Interaction between 
selectins and sLex mediates rolling adhesion of leukocytes alongside activated endothelial 
cells in inflammatory conditions. Fu et al. [24] synthesized a mimetic of sLex coupled to 
DTPA. The resulting Gd chelate, Gd-DTPA-B(sLeX)A was then tested in intracerebral 
injection of TNF and IL-1β, where a moderate increase in the MRI T1-weighted signal was 
seen at 50 minutes post contrast injection, while no difference was appreciated after 
injection of the nonspecific DTPA-Gd [25]. In the transient MCAO stroke model, the same 
agent was capable of detecting upregulation of E-/P-selectin in the infarcted brain region, 
again with relatively low sensitivity [26]. To address the issue of sensitivity, the same group 
developed MNP-PBP, a peptide ligand specific for P-selectin conjugated to a 50 nm 
diameter aminated dextran superparamagnetic iron oxide (SPIO) nanoparticle. This agent 
was again tested in the transient MCAO stroke model with improved but still suboptimal 
sensitivity [27].
To further increase sensitivity, a glyconanoparticle (GNP) reagent named GNP-sLex was 
designed to bind to E- and P-selectin. This nanoparticle bears 105 to 107 sLex moieties on 
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(USPIO). Using an unmodified control nanoparticle as a comparison proved specificity of 
GNP-sLex. After intracerebral injection of IL-1β, upregulation of E-/P-selectin was 
detectable in the injected hemisphere. These results were further corroborated in focal 
MOG-induced EAE and endothelin-1 (ET-1) induced stroke in rats (intracerebral injections). 
In both disease models, T2 hypointense areas were detected consistent with upregulation of 
E-/P-selectin in neuroinflammation [28]. Importantly, control nanoparticle did not reveal 
any changes, and injection of DTPA-Gd did not show BBB alterations or changes in CBV, 
confirming specificity and subclinical detection capability of this approach. In a follow-up 
study, this agent was also used to evaluate subclinical focal EAE lesions after reactivation 
with systemic LPS, where GNP-sLex was a highly sensitive marker for subclinical 
inflammatory foci (Figure 3D) [29].
Intercellular adhesion molecule 1 (ICAM-1, or CD54)
ICAM-1 is another endothelial cell expressed member of the immunoglobulin superfamily 
involved in adhesion of leukocytes to the endothelium. The first approach to perform MR 
imaging of an adhesion molecule, and in this case ICAM-1, was undertaken by Sipkins et al. 
[30], when they used an anti-ICAM-1 conjugated liposome chelate. Using ex vivo brain MR 
imaging after injection of their agent in the EAE model of MS, they were able to detect 
upregulation of ICAM-1 in the inflamed brain. Localization of this probe to the endothelium 
was confirmed with a Texas red tagged probe under fluorescence microscopy [30]. 
Subsequently, Deddens et al. [31] designed and tested two different probes targeted at 
ICAM-1. Their first probe, an anti-ICAM-1 functionalized Gd liposome (similar to the 
probe used by Sipkins et al. [30]) with a size of approximately 200 nm worked in vitro when 
tested in brain endothelial cells stimulated with TNF, but lacked sensitivity to detect 
ICAM-1 upregulation in a murine stroke model. In contrast, an anti-ICAM-1 functionalized 
MPIO (ICAM-MPIO) with a size of approximately 1 μm bound specifically to TNF-
stimulated brain endothelial cells in vitro, and showed T2 hypointense brain areas 1 hour 
after induction of the transient MCAO stroke model in vivo [31]. In a subsequent study 
using the same agent, upregulation of ICAM-1 in the brain after radiation injury could be 
visualized [32].
Integrin αvβ3
Integrin αvβ3, a cell adhesion molecule not only expressed on endothelial cell but also on 
macrophages and platelets, has also been targeted for non-invasive imaging. Peptides 
containing the three amino acid sequence arginine-glycine-aspartic acid, called RGD 
peptides, have been shown to be specific ligands for integrin αvβ3, and were labeled with 
radioactive tracers for PET and SPECT [33,34]. Two agents, 18F-galacto-RGB for PET 
and 99mTc-NC100692 for SPECT have been translated [35], but human studies have been 
restricted to evaluation of tumor angiogenesis and not neuroinflammation. In addition to 
nuclear imaging, MR imaging with RGD peptides conjugated to Gd-based paramagnetic 
nanoparticles [36], and USPIO-based superparamagnetic nanoparticles [37] were used to 
assess tumor angiogenesis. Furthermore fluorescent molecular tomography (FMT) with 
RGD-peptides conjugated to Cy5.5 [38] and quantum dots [39] have been reported. In a 
mouse model of glioma, Cy5.5-RGD binding was evaluated on fluorescence reflectance 
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timaging (FRI), and signal intensity correlated well with tumor size on MR imaging. Binding 
was blocked by pre-injection with unlabeled RGD, and Cy5.5 signal co-localized with 
vasculature on fluorescence microscopy [40]. Using a tetrameric 64Cu labeled RGD peptide, 
Wu et al. [41] similarly demonstrated rapid and significant probe uptake into mouse 
gliomas, and specificity was confirmed by pre-injection with unlabeled RGD to block 
binding sites.
Leukocyte Functions
Oxidative stress
Myeloperoxidase—Myeloperoxidase (MPO) is a proinflammatory and oxidative enzyme 
secreted by activated neutrophils and monocytes in inflamed tissues, facilitating the 
conversion of H2O2 to HOCl [42]. Querol et al. [43,44] synthesized the paramagnetic 
activatable MPO sensor Gd-bis-5-HT-DTPA (MPO-Gd). MPO oxidizes the sensor’s 5-
hydroxytryptophan (5-HT) moieties to results in two effects: 1) oligomerization of the 
sensor and 2) binding of the sensor to proteins. Both effects lead to an increase in T1 
relaxivity, and because the sensor is retained at sites of MPO activity, delayed image 
acquisition improves sensitivity and specificity [43]. Probe retention and biodistribution 
were investigated by labeling bis-5-HT-DTPA with 111In, and the MPO sensor was more 
than fourfold increased at MPO-rich sites [43].
Since then, MPO-Gd has been used in several neuroinflammatory diseases. In EAE, MPO-
Gd detected more and smaller active inflammatory brain lesions than DTPA-Gd (Figure 
4A), and MPO-expressing cells and demyelinated areas correlated well with MPO-Gd 
enhanced MR imaging findings [45]. In a subsequent study, a preclinical MPO-inhibitor was 
found to significantly ameliorate clinical disease in EAE mice by reducing infiltrating 
inflammatory cells and demyelination, and MPO inhibition resulted in reduced lesion 
volume, lesion number, and enhancement intensity on MPO-Gd enhanced MR imaging [46]. 
These findings suggest that MPO could be a potential treatment target and imaging 
biomarker in MS.
In the MCAO mouse model of stroke, MPO-Gd enhanced MR imaging detected widespread 
secretion of MPO into the ischemic areas, and MPO-Gd positive lesion volume correlated 
well with infarct size (Figure 4C) [47]. MPO-specific signal peaked on day 3 after stroke, 
which was confirmed using in vitro MPO activity and RT-PCR assays [47]. In addition, 
specificity of MPO-Gd in vivo was confirmed by imaging MPO-knockout stroke mice, in 
which no specific MPO enhancement was detected [47]. In a mouse model of silent brain 
ischemia induced by intra-arterial injection of microbeads or fractionated clots, MPO-Gd 
positive brain areas co-localized with embolic material [48].
Gliomas are known to trigger inflammation, and one clinical problem is to distinguish 
recurrent growth from inflammation. Kleijn et al. [49] injected rats intracerebrally with D74/
HveC glioma cells or mice with CT-2A cells, and treated the resulting gliomas with an 
oncolytic virus. MPO-Gd enhanced MRI detected the inflammatory changes induced by 
treatment with oncolytic virus longitudinally in vivo: On day 1 after virus injection, 
intratumoral MPO activity elevated. On days 3–7 after virus injection, while tumor size 
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tdecreased and intratumoral MPO activity decreased, peritumor MPO activity increased 
(Figure 4B). Upon translation, this might allow differentiation of tumor from inflammation.
Another approach to detect oxidative stress generated by the MPO system is based on 
emission of chemiluminescence by oxidizable probes. While luminol has been found to 
specific to MPO [50], lucigenin requires NADPH oxidase for activation [51]. Luminol has 
been used to visualize oxidative stress in vivo in a mouse model of stroke [52] and in EAE 
[53]. Because tissue absorption and light scattering are an issue for translation to humans, a 
chemilumescence resonance energy transfer methodology was recently described, where 
luminol emitted light excites nanoparticles to emit far-red fluorescence, resulting in signal 
amplification and reduced tissue absorption [54].
Free radicals—To detect free radicals, the radical spin trap 5,5-dimethyl-1-pyrroline N-
oxide (DMPO) was injected into mice followed by an antibody against DMPO conjugated to 
albumin-biotin-DTPA-Gd. This approach proved fruitful in a mouse model of diabetes, 
where in vivo MR imaging distinguished diabetic from control mice [55]. In mice with a 
mutant form of superoxide dismutase 1 (SOD1), which develop a disease resembling 
amyotrophic lateral sclerosis (ALS), DMPO imaging was also successful in detecting free 
radicals. There, T1 signal 120 minutes post agent injection was elevated compared to control 
mice, and probe retention in the spinal cord of ALS mice but not control mice was 
confirmed ex vivo with streptavidin-Cy3 (which binds to the biotinylated probe) on 
fluorescence microscopy [56]. This suggests successful detection of oxidative stress in vivo 
in a mouse model of ALS.
Electron paramagnetic resonance imaging (EPRI) in principle is capable of detecting 
unpaired electrons in free radicals, but because free radicals are short-lived and exist at very 
low concentrations in vivo, administration of imaging agents with unpaired electrons or 
precursors of such agents is necessary [57]. In the kainic acid model of epilepsy in rats, a 
BBB-permeable nitroxide radical was injected to evaluate the reduction capability of certain 
areas in the brain. In the hippocampus, the ability to reduce radical was diminished 
compared to other brain regions and to hippocampus of control animals [57], and these 
findings were confirmed in the FeCl3 seizure model [58]. Using an oxidizable precursor 
sensor, increased levels of oxidative stress were detected in hippocampus and striatum in 
kainic acid induced seizure [59]. In a mouse model of cerebral ischemia-reperfusion, 
nitroxide radical enhanced EPRI demonstrated impaired reduction ability in the ischemic 
brain [60]. With EPRI, one of the limitations is spatial resolution. Overhauser MR (OMR) 
imaging couples the sensitivity of EPRI with the spatial resolution of MRI by making use of 
the Overhauser effect [61]. In mice with cerebral ischemia-reperfusion, decreased reduction 
capacity was detected in the affected hemisphere with methoxycarbonly-PROXYL (a redox 
sensitive agent) on OMR imaging [62]. Similarly, in the 6-hydroxydopamine model of 
Parkinson’s disease, decreased reduction capacity was detected in the injected hemisphere 
[63].
Other approaches—Other approaches to image oxidative stress in vivo are less advanced, 
or have not been applied to study neuroinflammation. A PET agent named 18F-5-Fluoro-L-
Aminosuberic Acid (18F-FASu) is taken up by a cystine/glutamate transporter that is 
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tupregulated when cells experience oxidative stress to make substrate available for the 
antioxidant glutathione. 18F-FASu has been validated in vitro and in vivo using mouse 
xenograft tumors [64]. Peroxy Caged Luciferin-1 (PCL-1) is a bioluminescent probe specific 
for H2O2. In the presence of firefly luciferase and H2O2, luciferin is released from PCL-1 
and triggers bioluminescence. This system’s suitability for in vivo imaging has been 
demonstrated in a mouse model of prostate cancer [65]. Lastly, CePO4:Tb, Gd hollow 
nanoparticles have been described to form nanospheres in the presence of H2O2, thus 
making them potentially suitable for fluorescence and MR imaging [66], but have not been 
tested in vivo.
Proteolytic activity
Proteases such as matrix metalloproteinases (MMPs), which are a family of zinc-dependent 
endopeptidases with over 25 members, as well as cathepsins, which are cysteine proteases 
with at least 12 members, are crucial mediators of tissue damage secreted mostly by 
microglia, astrocytes, and monocytes/macrophages. MMPs degrade extracellular matrix and 
are associated with excitotoxicity, neuronal damage [67], and opening of the BBB [68].
MMPsense is an activatable near-infrared fluorescence probe that can be cleaved by various 
MMP types [69]. MMPsense has been used visualize MMP activity in stroke, where 
increased MMP activity on FRI was detected in the ischemic brain (Figure 5B–5C) [70]. 
MMPsense signal was detectable at 24 hours, remained elevated until day 7, and was 
inhibited by a preclinical MMP inhibitor [70], suggesting specificity of this probe.
Prosense is a similar activatable near-infrared fluorescence probe that can be cleaved by 
cathepsin, B, L, and S. It was first evaluated in the 9L gliosarcoma mouse model in the 
brain, where elevated fluorescence signal was detected using FMT [71]. The same probe 
was also used in a study utilizing nude mice implanted with U87 human glioma cells. FMT 
was fused with MR imaging by use of landmarks such as ears, eyes, snout, and tumor foci 
for better anatomical coregistration. Prosense signal location and intensity correlated well 
with tumor location and growth (Figure 5A), and the response to chemotherapy with 
temozolomide could be visualized [72]. A fluorescent sensor specific to cathepsin B (Cath B 
680 FAST) was successfully used in mice with EAE, where it distinguished EAE from 
control mice and demonstrated elevated cathepsin B activity in brain and spinal cord [73].
For nuclear imaging of MMPs, the MMP-3 inhibitor CGS 27023A has been radiolabeled 
with fluorine-18 (18F) for potential PET imaging [74]. An iodine-123 (123I) ligand of the 
same compound has been used to image vascular inflammation after carotid artery ligation 
with SPECT [75].
Other approaches include a radiolabeled antibody against MMP-14, which has been used to 
image inflammation in atherosclerotic ApoE deficient mice with SPECT [76], and the PET 
probe copper-64 (64Cu)-DOTA-CTT, which is based on the peptide MMP-2/9 inhibitor 
CTT, but poor in vivo stability and low affinity have halted further studies [77].
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COX-1 and 2 are key enzymes that catalyze conversion of arachidonic acid to 
prostaglandins, which play crucial roles in inflammation. While generally COX-1 is thought 
of as constitutively expressed, COX-2 is often upregulated during inflammation. However, 
in the brain it has been suggested that microglia express COX-1 and upregulate this enzyme 
in various inflammatory diseases, while COX-2 is mostly expressed by neurons in a 
constitutive way [78].
To visualize COX-1 activity, the PET ligand 11C-ketoprofen was successfully tested for 
specificity in COX-1 and COX-2 knockout mice. After intracerebral injection of LPS in rats, 
increased uptake of 11C-ketoprofen was seen as early as 6 hours and returned to baseline by 
day 7. This correlated with presence of COX-1 but not COX-2 expressing microglia at the 
site of injection [79]. Consistent with these findings, a PET agent selective for COX-2 did 
not show significant changes in a rat model of HSV encephalitis [80], and a different COX-2 
PET agent showed high uptake in the brain reflective of constitutive neuronal COX-2 
expression [81].
Glycoprotein IIb/IIIA (GPIIb/IIIa)
GPIIb/IIIa is an integrin complex found on platelets, and is important for platelet activation. 
In cerebral malaria, extensive damage to vascular endothelial cells and platelet thrombi are 
typical disease features, and related to platelet activation via GPIIb/IIIa. Von zur Muhlen et 
al. [82] have conjugated a single-chain antibody directed against the ligand-induced 
bindings sites (LIBS) of GPIIb/IIIa on platelets to MPIO. The resulting agent LIBS-MPIO 
specifically detects the LIBS epitope, which is only exposed upon platelet activation. In a 
mouse model of cerebral malaria, using LIBS-MPIO enhanced MR imaging, they were able 
to detect activated platelets in the brain vasculature at a stage when conventional MR 
imaging was negative and clinical findings absent.
Translocator protein (TSPO)
TSPO (formerly peripheral benzodiazepine receptor) is not expressed on neurons but rather 
micro- and macroglial cells, and is upregulated with microglia and astrocyte activation in 
different neuroinflammatory conditions as measured with PK11195, a specific ligand for 
TSPO [83,84]. However, subsequent studies revealed that binding of PK11195 correlated 
better with the number of activated microglia/infiltrated monocytes than astrocytes in 
models of TBI and stroke [85,86]. In rats induced with stroke, carbon-11 (11C)-PK11195 
PET revealed microglia activation/monocyte infiltration into the infarct [87] This was 
subsequently confirmed in a human stroke patient, where 11C-PK11195 enhanced PET 
showed increased uptake in the affected hemisphere 13 and 20 days after stroke [88]. 
Moreover, PK11195 binding co-localized with activated microglia in a mouse model of 
Alzheimer’s disease [89]. Investigating microglia activation with 11C-PK11195 in 8 patients 
with Alzheimer’s disease, increased 11C-PK11195 uptake was observed in the entorhinal, 
temporoparietal and cingulate cortex (Figure 6A) [90].
Since then, 11C-PK11195 PET has been used in a variety of neuroinflammatory diseases 
both in rodents and humans. In a mouse model of TBI, prolonged microglia activation was 
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tdetected 10 days after the insult [91]. In 10 patients with TBI, there was no increased 
binding of 11C-PK11195 PET at the original site of focal brain injury, but in the thalamus, 
putamen, internal capsule, and occipital cortices (Figure 6C). Additionally, microglia 
activation could be detected even 17 years after TBI, suggesting a potential for therapeutic 
intervention even at this time point [92].
In a study of 6 stroke patients, microglia activation was observed as early as day 3 post 
stroke, first at the outer rim of the infarct and spreading to the core (Figure 6B), but was also 
seen in distant brain areas consistent with Wallerian degeneration [93]. In 18 stroke patients 
imaged between 2 weeks and 6 months post symptom onset, microglia activation in the 
infarct was initially elevated, normalized over the study period, but– if prolonged – 
correlated negatively with clinical outcome. In addition to microglia in the infarct, there was 
prolonged microglia activation along the damaged pyramidal tract (PD) in the brainstem in 
patients where the PD was affected, and this correlated positively with clinical outcome 
[94]. These results support the hypothesis that microglia have both neurotoxic and 
neuroprotective functions depending on location and timing.
In a study on 12 patients with MS, microglia activation was not only detected in areas 
correlating with lesions detected on conventional MRI, but also in normal-appearing areas 
including cortical areas [95]. Furthermore, 11C-PK11195 binding in cortical areas correlated 
with clinical disability in a study of 18 RR and SP-MS patients [96]. In a PET-MRI 
correlation study on 22 MS patients, 11C-PK11195 binding was increased in DTPA-Gd 
enhancing lesions but was decreased in T2-lesions. However, during a relapse, an increase in 
normal-appearing white matter as well as transient increased uptake in T2-lesions was seen 
[97]. Lastly, 11C-PK11195 uptake in normal-appearing white matter increased with the 
degree of brain atrophy [98]. These results suggest that microglia activation is present 
outside of MRI-detected lesions, and that microglia activation contributes to both relapses 
and chronic progression in MS.
In two patients with Rasmussen’s encephalitis, PET imaging with 11C-PK11195 showed 
diffuse and focal increase in signal throughout the affected hemisphere consistent with 
postmortem neuropathological studies of diffuse microglia activation [99]. Microglia 
activation was also detected in the brains of patients with Parkinson’s disease and ALS 
[100,101], in spinal cords of rats after sciatic nerve injury [102], and in striatum of patients 
with Huntington’s disease [103].
Although 11C-PK11195 has been widely used in both animal and human research, it suffers 
several set-backs: It is associated with a high level of nonspecific binding, and has a poor 
signal-to-noise ratio [104,105]. In addition, 11C has a very short half-life of only 20 minutes 
which also negatively affects widespread clinical use. Therefore, several alternative TSPO 
agents have been synthesized [106].
Several second generation TSPO agents were tested in neuroinflammatory models on ex 
vivo autoradiography: The benzodiazepine Ro5-4864 was radiolabeled with 125I and 
evaluated in the rat C6 glioma model, with increased probe uptake in the tumor [107]. 18F 
labeled PK14105 and 11C labeled AC-5216 were compared to PK11195 in rodents 
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tintracerebrally injected with kainic acid, and demonstrated similar characteristics [108,109]. 
Price et al. [110] tested three compounds in a rat model of Huntington’s disease, but the 
compound with the highest contrast over normal-appearing brain had similar characteristics 
as 11C-PK11195. 123I-CLINDE was used in rat EAE and the cuprizone mouse model of 
demyelination [111,112].
Most promising are agents that have been directly compared to 11C-PK11195 in in vivo PET 
studies, or have been conjugated with radiolabels that have better characteristics than 11C, 
such as 18F. For example, 11C-DAA1106 showed specific binding 5 times higher than 11C-
PK11195 in rodent models of Parkinson’s disease and TBI [113,114]. A slightly improved 
tracer, 18F-fluorethyl-DAA1106 was capable of visualizing inflammation in APP23 
Alzheimer’s mice [115]. However, in patients, no difference was detected between 
Alzheimer’s patients and control patients [116], or between MS patients and control patients 
[117], suggesting different receptor-ligand interaction depending on the species.
After intracerebral injection of the excitotoxin AMPA, the tracer 11C-CLINME identified 
inflamed brain tissue with higher binding potential compared to PK11195 [118]. 18F-
PBR111, the fluorinated version of 11C-CLINME, has been used to image acute and chronic 
EAE [119], and is currently undergoing a clinical trial on MS patients. 11C-vinpocetine 
showed favorable characteristics compared to 11C-PK11195 in four patients with stroke 
[120], and the sensitivity of 11C-vinpocetine for activated microglia was confirmed in a 
study of 9 stroke patients [121]. The same agent detected elevated microglia activation in 
elderly compared to young subjects, but failed to detect a difference between elderly 
subjects and patients with Alzheimer’s disease [122]. 11C-PBR28 was successfully tested in 
the MCAO rat stroke model, and demonstrated microglia activation in the outer infarct rim 
[123]. In MS patients, 11C-PBR28 binding was seen in active inflammatory lesions 
confirmed with contrast-enhanced MR imaging (Figure 6D), and sometimes preceded 
appearance of MRI lesions [124]. Other agents include 18F-DPA714, which has been tested 
in EAE and rodent herpes encephalitis [125,126], and demonstrated higher contrast-to-noise 
ratios than 11C-PK11195 in a murine stroke [127].
Challenges in optimizing TSPO agents for human imaging include interspecies variations in 
affinity of different agents, which makes extrapolation of rodent studies difficult to 
impossible, as well as recent discovery of a polymorphism in the TSPO gene that determines 
binding affinity to TSPO, which affects all agents but 11C-PK11195 [128].
Cannabinoid receptor 2 (CB2)
While the cannabinoid receptor 1 is constitutively expressed in a variety of cell types, CB2 
is thought to be expressed on microglia/macrophages and is upregulated with activation of 
these cells [129]. Horti et al. [130] evaluated 11C-A836339, a selective CB2 agonist, as a 
candidate probe for neuroinflammation and specifically for activated microglia. They found 
increased uptake with LPS-induced neuroinflammation and in the transgenic APPswe mouse 
model of Alzheimer’s disease. A similar probe, 11C-KD2 showed increased uptake in spinal 
cord sections from ALS patients on autoradiography [131]. However, another probe, 11C-
NE40 did not detect a difference between stroke and sham-operated rats in the 
photothrombotic stroke model [132]. Lastly, a near-infrared probe selective for CB2 has 
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tbeen developed and successfully tested in a mouse tumor model [133]. The major challenge 
for CB2 imaging is specificity of CB2 for microglia/macrophages, because in 
neuroinflammation CB2 can be detected on T-lymphocytes, astrocytes, and microglia [134].
Leukocyte Labeling
Radiolabels
Decades ago, leukocytes were harvested from blood samples, labeled with indium-111 
(111In) and re-injected to localize inflammation on SPECT. While first studies were mostly 
on sepsis foci detection [135–137], further studies extended the use of this approach to 
cerebral abscesses [138], brain metastases [139], and stroke [140]. However, 111In labeling 
damages leukocytes and this results in reduced proliferative capacity and DNA damage 
[141]. To circumvent this, technetium-99m (99mTc) has been used, which carries a much 
lower risk of leukocyte damage [142]. In stroke, patients injected with 99mTc-labeled 
leukocytes with poor outcome had higher signal in the affected hemisphere compared to 
patients with good outcome, suggesting a clinically relevant effect of leukocyte infiltration 
[143]. Wang et al. [144] demonstrated that 99mTc-leukocyte signal is higher in acute than 
chronic stroke and that signal persists for several weeks. In a larger study on 88 stroke 
patients, leukocytes accumulated in infarcted brain areas and this correlated with brain tissue 
damage and poor neurological outcome [145]. To specifically track neutrophils, Price et al. 
[146] labeled these cells in vitro with 111In-troponolate. In 15 stroke patients, they found 
that neutrophils recruit to the infarcted brain within 24 hours (Figure 7A), and degree of 
neutrophil recruitment correlated with infarct extension [146].
Since then, this method has been adapted for PET imaging by labeling autologous cells 
with 18F-FDG and re-injecting them into patients. In a pilot study on 21 patients with fever 
of unknown etiology or unknown extent of infection, PET/CT imaging demonstrated general 
feasibility [147]. Additionally, labeling of leukocytes with 64Cu has been published [148].
However, there are several shortcomings of this approach: first, release of the radiolabel 
from the cells, which can penetrate a compromised BBB, leads to non-specific signal [149]; 
second, intraparenchymal versus intravascular signal cannot be distinguished [149]; third, 
false positive (e.g., GI bleeding, pseudoaneurysms, and tumors) and false negative 
(encapsulated nonpyogenic abscess, chronic low-grade infection, hyperglycemia, steroids) 
results are not uncommon [150]. Finally, length of follow up depends on the half-life of the 
radiolabel and on the proliferative capacity of the labeled cells (dilution of label per cell with 
signal loss).
Iron oxide particles
Superparamagnetic iron oxide particles consist of an iron-oxide core embedded in dextran, 
citrate, or polymer shell, and several different particle sizes exist: ultra-small 
superparamagnetic iron oxide (USPIO, 10 – 50 nm), superparamagnetic iron oxide (SPIO, 
50 – 100 nm), and micrometer-sized iron oxide (MPIO, >1 μm) [151]. These agents possess 
large negative magnetic susceptibilities, resulting in negative contrast on T2-weighted 
sequences. Virtually any cell type can be labeled in vitro with different-sized iron oxide 
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tnanoparticles, although for cells that do not phagocytose a transfection agent might be 
needed to increase iron oxide uptake [151].
Two main approaches in how iron oxide particles are used to image neuroinflammation 
exist: in the first, iron oxide is injected intravenously and taken up by phagocytic cells (e.g. 
monocytes, macrophages, microglia) in vivo, which are thus labeled, and the second, where 
autologous cells are harvested and labeled in vitro, then re-injected to trace the labeled cells.
Iron oxide labeling in vitro—In one of the few studies on iron oxide leukocyte labeling 
in neuroinflammation, Stroh et al. [152] isolated splenic mononuclear cells and labeled them 
with USPIO before systemic reinjection into stroke mice. They were able to detect injected 
cells at 48 hours in the lesion border for up to 5 weeks post stroke [152]. In a proof-of-
concept study, human monocytes were labeled with superparamagnetic iron oxide (SPIO, 
Feridex, size 120–160 nm), which were injected into the basal ganglia of SCID mice. The 
SPIO nanoparticles were tracked by MRI for up to 14 days after injection, and MR imaging 
localization of monocytes was confirmed on histology [153].
Yeh et al. [154] labeled rat T-lymphocytes in vitro with USPIO, which took up by these 
cells via endocytosis, and reinjected them into the same rats for tracking by MRI. Anderson 
et al. [155] used SPIO-poly-L-lysine to label T-lymphocytes in vitro, before stimulation and 
adoptive transfer of these cells into recipient mice to induce EAE. SPIO-labeled T-
lymphocytes were readily detected in the spinal cord of mice on in vivo and ex vivo MRI 
(Figure 7B) [155]. Using a similar approach, T-lymphocytes were labeled with SPIO in the 
presence of the transfection reagent protamine sulfate, which increased labeling efficiency 
and also allowed for detection of injected cells in the spinal cord on MRI [156].
Iron oxide particle labeling in vitro shares similar issues with radiolabeling. Cells might lose 
the label or die, both of which will result in nonspecific signal, and cell proliferation will 
dilute the signal. Both effects pose a limit on the time window of imaging. For clinical 
safety and validity of study results, any effects of iron oxide particles on their target cells 
need to be addressed. In one in vitro study, iron oxide nanoparticles did not affect 
proliferative capacity of a human macrophage cell line but transiently increased oxidative 
stress [157], consistent with phagocytic oxidative burst after phagocytosis of these particles. 
In addition, phagocytosis of SPIO or USPIO shifted rat and mouse macrophages towards an 
anti-inflammatory phenotype [158].
Another limitation is the restriction to one label with MR imaging (in contrast to 
fluorescence imaging, which can distinguish labels based on excitation and emission 
wavelength). Thus, cell co-localization and interaction cannot be investigated with 
conventional MR imaging and gadolinium or iron oxide based contrast agents. Recently, 
however, an interesting approach utilizing paramagnetic chemical exchange saturation 
transfer agents has been reported. There, lanthanides such as Yb and Eu are conjugated to 
HPDO3A, and these agents have similar pharmacokinetic and biosafety properties as Gd-
HPDO3A. Using these agents, two different cell lines were labeled and could easily be 
distinguished in vitro as well as in vivo after injection into mice [159].
Pulli and Chen Page 13
J Clin Cell Immunol. Author manuscript; available in PMC 2014 December 16.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tPhagocytosis/uptake in vivo—The first study using iron oxide to track cells that take 
up iron oxide particles via phago- or endocytosis in vivo was in a rat glioma model using C6 
cells. C6 cells are known to phagocytose, and uptake of monocrystalline iron oxide 
nanoparticles (MION) of 20 nm diameter was shown in vitro by radionuclide and 
fluorescent labeling of MION. In vivo, gliomas showed uptake of MION on MRI [160]. In a 
human study involving 55 patients, in 19 of 34 glial tumors iron oxide enhanced as much or 
more than DTPA-Gd [161]. Taschner et al. [162] reported USPIO enhancement in 7 of 9 
glioma patients, but only detected USPIO in macrophages in 2 patients, casting doubt on the 
cellular identity imaged with this approach.
For most other neuroinflammatory diseases, however, the ability of certain leukocytes 
(macrophages, neutrophils, monocytes, microglia, dendritic cells) to phagocytose iron oxide 
nanoparticles has been used in an attempt to specifically visualize these cells.
In the rat EAE model, USPIO-enhanced MR imaging, lesions of low T2 signal were seen 
and histologically confirmed to be phagocytic leukocytes [163]. When comparing USPIO 
enhancement (phagocytes) to DOTA-Gd enhancement (BBB breakdown), uptake of USPIO 
was detected in areas without DOTA-Gd enhancement, and vice versa (Figure 8A) [10]. In 
addition, USPIO enhancing lesions had low magnetization transfer ratios, possibly 
indicating co-localization of phagocytic cells with areas of demyelination [10]. USPIO 
lesion load and volume at the acute EAE stage correlated with inflammation, phagocyte 
infiltration, demyelination, axonal damage and extent of axonal loss [164].
In a study investigating BBB breakdown with DTPA-Gd and phagocyte infiltration with 
USPIO suggested that BBB breakdown preceded phagocyte infiltration in acute EAE [165]. 
In 19 patients with relapsing-remitting (RR)MS, who underwent serial MR imaging with 
USPIO and DTPA-Gd, 188 USPIO positive lesions were seen, 144 of which did not show 
DTPA-Gd enhancement. Of 59 lesions with DTPA-Gd enhancement, 15 did not show 
USPIO uptake, and USPIO uptake preceded DTPA-Gd enhancement in some lesions 
(Figure 8B) [166]. These results suggests that BBB breakdown and phagocyte infiltration 
are different pathophysiological events and might occur independently of each other at 
different stages or types of MS lesions, with no clear temporal relationship.
In the transient MCAO stroke model in rats, USPIO could be detected in vessels 24 hours 
after administration, and in infarcted tissue on day 2, consistent with neutrophil and 
monocyte infiltration at this time [167]. Localization of USPIO within phagocytic cells was 
confirmed on histology [168]. Wiart et al. [169] demonstrated peri-infarct USPIO uptake 
followed by signal spread to the contralateral hemisphere, correlating with areas of 
inflammation on histology. In a rat model of cerebral ischemia-reperfusion, SPIO uptake 
was mostly seen in the damaged brain and corresponded to areas of macrophages infiltration 
on histology [170]. To further clarify the timing of phagocytosis and possible cell migration, 
USPIO was injected on day 0 and uptake in stroke was investigated from days 1–7 after 
permanent MCAO in rats, and the following pattern was found: first, phagocytic cells 
accumulated in the boundary zone, then they were found in the infarct core on days 2–4, 
before clearing by day 7 (Figure 8C) [171]. This raised the question whether these cells 
could migrate into the ischemic lesion from the periphery. To address this question, the 
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tphotothrombotic stroke model in rats, which yields highly reproducible infarcts without 
surrounding penumbra, was utilized. MR imaging was performed on days 3, 6, 8, and 14 
post stroke induction, and 24 hours after injection of USPIO. On day 6, the outer infarct rim 
showed USPIO uptake, while by day 8 the infarct core was T2 hypointense [172]. In 
addition, there was BBB breakdown as evidenced by DTPA-Gd enhancement at all time 
points, indicating that BBB breakdown and phagocyte infiltration are unrelated [172]. 
Interestingly, when USPIO were injected on day 5, an outer rim of USPIO uptake was 
detected on days 6 and 8, indicating that phagocytes remain sessile [172]. Importantly, while 
macrophages were still found in infarcted tissue on day 14, no USPIO uptake was detected 
[172], suggesting a switch toward a non-phagocytic phenotype.
In a study on 10 ischemic stroke patients injected with USPIO 7 days after symptoms onset, 
USPIO uptake was seen in ischemic brain area and differed from DTPA-Gd indicated BBB 
breakdown, showing that phagocyte imaging is feasible in stroke patients (Figure 8D) [173]. 
In a second study of 10 stroke patients, USPIO volume did not correlate with DWI volume 
or BBB disruption, also suggesting that iron oxide MR imaging could provide information 
in addition to infarct size [174].
A central question when tracking phagocytic cells in the brain with iron oxide particles is 
when cells took up the particles. The first possibility is that circulating leukocytes 
phagocytosed particles in the blood stream and subsequently infiltrate into the brain. The 
second is that already infiltrated or resident microglia phagocytosed particles in the brain in 
situ. In the latter case, nonspecific signal from passage of particles through an impaired BBB 
can be problematic. Disrupting the BBB using the freezing lesion model, dextran-coated 
iron oxide (approximately 50 nm in size) was detected in endothelial cells on electron 
microscopy after 1 hour and persisted for 4–8 hours. On MRI, iron oxide enhancement was 
seen consistent with BBB breakdown [175]. After opening the BBB with mannitol, both 
MION (size 20 nm) and SPIO (size 200 nm) led to enhancement in the entire hemisphere. 
While MION was detected in the intercellular space, SPIO were found in endothelial cells 
but did no cross the basement membrane [176]. These findings indicate that the size of iron 
oxide particles may determine passage through an impaired BBB. In an experiment using 
crush injury of the sciatic and optic nerve, Bendszus et al. [177] detected USPIO uptake in 
sciatic nerve where they also found monocyte infiltration, but did not detect USPIO uptake 
in the optic nerve where they found microglia activation without monocyte infiltration. 
These findings suggest that phagocytes take up iron oxide in the blood en route to the brain. 
However, a study comparing USPIO injection versus re-injection of in vitro SPIO-labeled 
monocytes in photothrombotic stroke found that contrast enhancement was markedly 
different. While USPIO enhancement was seen within hours, SPIO labeled monocytes were 
not detected until after 72 hours, suggesting that USPIO does not represent signals from 
monocytes labeled en route to the brain but rather nonspecific penetration of the BBB or 
endothelial cell uptake [178]. Therefore, caution and careful validation need to be performed 
when tracking cell using parenterally injected iron oxide nanoparticles. In vitro labeling of 
the cells prior to injection should be preferred to avoid nonspecific signal.
Another potential issue with iron oxide phagocytosis is that phagocytosis per se does not 
differentiate between tissue damage and repair, as pro-inflammatory cells as well as anti-
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tinflammatory cell can phagocytose. In human monocytes, it has been shown that CD14++ 
CD16- classic (proinflammatory) monocytes phagocytose significantly more iron oxide than 
CD14++ CD16+ non-classical (anti-inflammatory) monocytes, as tested with three different 
SPIO agents (Ferumoxides, Ferucarbotran, CLIO) and one MION agent (MPIO-48) in vitro 
[179]. However, both monocyte subsets did take up all four particle types. This distinction is 
of clinical relevance, because in MS, macrophages that have phagocytosed myelin have 
been shown to be of the anti-inflammatory (repair) M2 phenotype [180]. Thus, one needs to 
corroborate the imaging findings against other datasets to ascertain the type of the cells 
imaged.
Perfluorocarbons 19F-MRI, Gadofluorine M
Another approach to phagocytic cell labeling is fluorine 19F-MR imaging. In stroke mice 
injected with nanoemulsions of perfluorocarbons increased (19F) MR signal was detected in 
the border zone of ischemia, and these areas were confirmed to contain phagocytic 
leukocytes on histology [181]. Gadofluorine M is a gadolinium based agent with a 
perfluorinated side chain which forms small aggregates and micelles in solution 
approximately 5 nm in diameter [182]. Phagocytes and endothelial cells have been shown to 
take up this agent, and in a study on EAE, more lesions were detected compared to DTPA-
Gd, with signal corresponding to areas of inflammation and demyelination [183]. 
Gadofluorine M also can be used to label cells in vitro, as shown with monocytes that could 
be detected on MR imaging for up to 7 days [184]. Little specificity data is available for 
these agents for phagocytosis imaging. However, given the size of these two agents, they 
may share similar limitations as USPIO nanoparticles regarding cell phenotype and 
nonspecific leakage.
Specific cell subset labeling
Neutrophils: Neutrophils was first imaged with SPECT using 99mTc-anti-CD15 (LeuTech) 
[185,186] an anti-granulocyte fab fragment of anti-NCA-90 conjugated to 99mTc 
(LeukoScan) [187], or BW 250/183 anti-granulocyte antibody [188]. Another approach is to 
use formyl peptides, which comprise of a large group of heterogeneous molecules (e.g. 
Lipoxin A4, fMLF from E.coli, humanin) that bind to the formyl peptide receptor (FPR) 
group. FRP1 is mostly expressed on neutrophils and mediates migration to the site of 
inflammation [189]. 111In or 99mTc labeled synthetic fMLF was successfully used to detect 
bacterial infection in experimental models [190,191], but it has been known to cause 
neutrophil activation and degranulation, making these compounds less desirable as imaging 
agents. The peptide cFLFLF is a high affinity antagonist for FRP1 and has been labeled 
with 64Cu resulting in the PET agent 64CU-PEG-cFLFLFK. This agent has been used to 
image lung inflammation [192]. The same peptide has been labeled with 99mTc for SPECT, 
Cy7 for fluorescence imaging, and gadolinium for MRI [193–195]. Neutrophils also had 
been imaged using radiolabeled IL-8 [196], which binds to the IL-8 receptor on neutrophils 
and is important for chemotaxis, and a radiolabeled peptide binding to PF4/CXCL-4 [197], 
another important chemoattractant for neutrophils. However, none of these neutrophil 
labeling agents have been used to image neuroinflammation. Thus, neutrophil imaging is an 
untapped area of research and translation for neuroinflammation.
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antibodies against CD3 and CD4, which were used to detect models of rheumatoid arthritis 
[198,199]. Radiolabeled cytokines such as IL-1 and IL-2 for SPECT were also used to detect 
inflammation in rheumatoid arthritis [200] and other autoimmune diseases [201, 202]. 
Recently, IL-2 was radiolabeled for PET with 18F resulting in 18F-FB-IL2, which was able 
to detect activated T-lymphocytes injected into SCID mice [203]. Unfortunately, injecting 
even small doses of cytokines often results in intolerable side effects.
Using an optical imaging approach, Berger et al. [204] labeled T-lymphocytes in vitro with 
Cy5.5-Tat, and tracked these cells to the brains of EAE mice after intravenous injection 
using FRI. Refining this approach, Costa et al. [205] isolated MBP TCR-Tg CD4+ TH 
lymphocytes and genetically engineered them to express GFP and luciferase. After injection 
into EAE mice, cells were tracked with bioluminescence imaging, and CD4+ TH 
lymphocytes were found first at sites of immunization and within the brain a few days later, 
persisting up to 50 days (Figure 7C) [205].
In an elegant proof-of-concept study in one patient with glioma, Yaghoubi et al. [206] 
genetically engineered autologous cytolytic CD8+ T lymphocytes to express the IL-13 
zetakine gene and herpes simplex virus 1 thymidine kinase suicide gene. The former 
facilitates targeting of these cells to glioma cells, while the activity of the latter can be 
imaging with PET using the radiotracer 18F-FHBG (Figure 7D) [206]. This approach 
allowed for selective PET imaging after injection of genetically engineered lymphocytes, 
and avoided cell label loss or dilution.
B-cells—99mTc-labeled rituximab (anti-CD20) has been used to image B-cell infiltration in 
patients with RA, Sjogren’s syndrome, Behcet’s disease, and sarcoidosis, but not yet in 
neuroinflammation [207]. Similarly, radiolabeled anti-CD19 and CD22 antibodies have been 
reported for B-cell imaging [208,209].
Monocytes/macrophages—99mTc-labeled nanobodies directed against the macrophage 
mannose receptor have been utilized for SPECT in a mouse model of rheumatoid arthritis 
[210]. Similarly, the macrophage folate receptor has been targeted with a 68Ga labeled PET 
probe to detect foreign body reactions in a mouse model [211]. Lastly, radiolabeled CCL2/
MCP-1 (a chemoattractant for monocytes) was used to visualize sterile inflammation in rats 
[212], and atherosclerosis in rabbits [213].
CD40 on antigen-presenting cells (APC)—CD40 is required for activation of APCs, 
and binds to CD40L on Th lymphocytes. In the transient MCAO stroke model in mice, a 
monoclonal antibody against CD40 was conjugated to Cy5.5 and used to evaluate CD40 
expression in the brain. No difference was seen in sham or stroke mice injected with Cy5.5-
labeled control antibody, and sham or CD40 knockout stroke mice receiving Cy5.5-CD40, 
proving specificity. Increased fluorescent signal in the affected hemisphere was only seen in 
vivo in stroke mice injected with Cy5.5-CD40. Areas of CD40 signal corresponded to 
ischemic areas on TTC staining, and on histology CD40 signal partially co-localized with 
microglia and partially with cells in the vasculature [214].
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Demyelination
Demyelination is one of the consequences of neuroinflammation, especially in MS. While 
MRI has been used to evaluate myelination, all available techniques suffer from low 
specificity towards myelin [215,216].
Recently, a Congo red derivative named BMB, which shows spontaneous fluorescence, was 
synthesized and shown to specifically bind to myelin tracts on histology. In addition, this 
probe crossed the intact BBB and was sensitive to demyelination in two different 
dysmyelinating mutant mice, in brain slices from MS patients, and after radiolabeling 
with 11C for PET visualized myelin tracts in the brain of baboons [217]. A similar 
compound with higher solubility, named case imaging compound (CIC) was developed by 
the same group and shown to penetrate the BBB and bind to myelinated areas in the 
brain. 11C-labeled CIC was successfully used in longitudinal PET imaging in rats injected 
with lysolethicin to induce focal demyelination followed by remyelination [218].
Wu et al. [219] synthetized several PET agent candidates that somewhat resemble the 
chemical structure of luxol blue, a histological stain used to observe myelin. These 
compounds are thought to bind to myelin through direct and specific interaction with MBP. 
Their lead compound MeDAS was labeled with 11C, bound specifically to myelin (Figure 
9A) and reliably distinguished PLP-Akt-DD mice, which develop hypermyelination, from 
wildtype mice [220]. In a study involving intracerebral injection of LPS to induce 
neuroinflammation without demyelination, focal demyelination, and EAE, 11C-MeDAS 
enhanced PET imaging demonstrated that agent uptake is unchanged after LPS injection, but 
uptake correlated with demyelination in lysophosphatidylcholine induced focal 
demyelination and EAE (Figure 9B) [221]. In a direct comparison study of 11C-CIC 
and 11C-MeDAS in the cuprizone mouse model, the latter showed superior correlation of de- 
and remyelination on PET [222].
For optical in vivo imaging on FRI, the compound DBT, a similar agent that emits 
fluorescence light in the near-infrared spectrum was capable of visualizing and quantifying 
myelination in hypermyelinated PLP-Akt-DD mice, hypomyelinated shiverer mice, and the 
process of demyelination and remyelination following treatment with cuprizone (Figure 9D) 
[223].
Case myelin compound (CMC) is another compound that specifically binds to myelin. 
Conjugated to DOTA-Gd, CMC bound to myelin in mouse brain sections but did not cross 
the BBB [224]. When DOTA-Gd-CMC was injected intraventricularly and MR imaging was 
performed at various time points after injection, MR signal corresponded to myelination on 
histology. In addition, DOTA-Gd-CMC enhanced MR imaging was capable of detecting 
focal demyelination induced by injection of lysophosphatidylcholine [225]. Similarly, a 
second MR probe, Gd-DODAS was also found to bind to myelin after intracerebral injection 
[226].
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amyloid and has been used in clinical PET studies in Alzheimer’s patients. However, this 
compound was also shown to bind to myelin, identified demyelinated lesions on brain slices 
from MS patients, and was subsequently used for PET imaging of two patients with MS. 
There, lesions seen on MRI had lower 11C-PIB uptake compared to normal-appearing white 
matter, and DTPA-Gd enhancing lesions showed more 11C-PIB uptake than non-enhancing 
lesions, consistent with active inflammation and beginning demyelination versus chronic 
inflammation with more severe demyelination (Figure 9C) [227].
Neuronal death
Probably the most important consequence of neuroinflammation is damage to neurons. In 
MS, neuronal loss correlates significantly with disease progression and irreversible disability 
[228,229]. In stroke, the “time is brain” paradigm underlines the importance of early 
treatment to prevent neuronal death and its clinical consequences [230].
The central benzodiazepine receptor, which can be targeted with 11C-flumazenil enhanced 
PET, is expressed on neurons and has been shown to be good marker for neuron integrity in 
stroke [231,232]. In patients with Alzheimer’s disease, reduction of 11C-flumazenil binding 
corresponded precisely with areas of neuronal loss on postmortem histology (Figure 10A) 
[233]. In epilepsy, it revealed neuronal loss in the epileptogenic focus [234]. For MS, an 
ongoing trial is going to evaluate the prognostic value of neuronal damage as assessed 
by 11C-flumazenil PET in early MS. However, this technique might not be sensitive enough 
to detect neuronal loss in hyperacute ischemia [235], and could be confounded in diseases 
affecting the GABA neurotransmitter system such as epilepsy [236].
A more specific approach to imaging of neuronal death is targeting annexin-V. Annexin-V 
is a protein that binds with high affinity to apoptotic cells expressing phosphatidylserine 
(PS) on their cell surface [237]. Using 99mTc labeled annexin-V, apoptosis was successfully 
detected on SPECT imaging in mouse models of fulminant hepatic apoptosis, acute cardiac 
transplant rejection, and cyclophosphamide treatment of a murine B cell lymphoma [238]. In 
a first clinical trial, 99mTc-annexin-V showed increase uptake in 5 out of 18 patients after 
cardiac transplant, of whom all showed at least moderate transplant rejection and apoptosis 
on histology [239]. Since then, this probe has been used to detect neuronal damage 
corresponding to CT images in 12 acute ischemic stroke patients [240], and has 
demonstrated increased probe uptake in the cortex but not cerebellum of patients with 
Alzheimer’s disease [241]. For fluorescence imaging, Cy5.5 labeled annexin-V has been 
used in a mouse model of ischemic stroke to visualize neuronal death on FRI (Figure 10B) 
[242]. In addition, CLIO-labeled annexin-V for MR imaging [243], and 18F-labeled 
annexin-V for PET imaging [244] have been reported.
Caspases are cysteine-aspartic proteases that are crucially involved in cell death. They are 
grouped into an execution group (caspases 3, 6 and 7) and an initiation group (capases 8 and 
10). Activation of the latter group is mediated via an intrinsic (release of cytochrome c from 
mitochondria) or extrinsic (via TNF, TRAIL, or FasL) pathway. Utilizing a far-red 
fluorescent pan-caspase inhibitor (NIR-VAD-fmk), Lawson et al. [245] identified activated 
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t(cleaved) caspases in brains of mice infected with prions using FRI, and this correlated with 
elevated levels of activated caspase-3 in the brain.
Other compounds belonging to the small molecule Aposense family have been designed. 
The small molecule DDC was radiolabeled with 3H for ex vivo autoradiography and detected 
neuronal death in rodent models of ischemic stroke and TBI [246,247]. Another small 
molecule, ML-10 was radiolabeled with 18F for PET imaging and studied in the MCAO 
mouse model of ischemic stroke. 18F-ML-10 was taken up into apoptotic but not necrotic 
cells in vitro, penetrated an intact BBB, increased signal in the affected hemisphere (Figure 
10D), with areas with probe uptake correlated well with TUNEL+ areas on histology 
[248]. 18F-DFNSH enhanced PET was used in postnatal day 7 rats treated with ketamine 
anesthesia, which has been shown induce neuronal apoptosis [249]. Lastly, the compound 
GSAO rapidly accumulates in the cytoplasm of dying cells, coinciding with loss of plasma 
membrane integrity. Labeled with the near-infrared fluorochrome AF750, GSAO allowed 
for visualization of neuronal damage with FRI in a mouse model of TBI (Figure 10C), and 
signal correlated with apoptotic neurons on TUNEL stain on histology [250].
Conclusion
Neuroinflammation is a highly complex process involving many different cell types and 
signaling molecules with the aim to control, regenerate, and repair. Under pathological 
conditions, however, neuronal loss and demyelination result in clinical disease and 
disability. The limited regenerative capacity of the brain makes early diagnosis and 
treatment the ultimate goal, and non-invasive molecular imaging of key players in the 
inflammation cascade holds promise for identification and quantification of the disease 
process before it is too late for effective therapeutic intervention. This would lead to early 
diagnosis and localization of pathology, better prediction of responders to treatment, and 
improved monitoring of treatment response. Additionally, many molecular imaging 
techniques are highly suitable to aid drug development in preclinical and clinical studies by 
allowing noninvasive longitudinal quantification of disease activity in the same subject.
Techniques such as TSPO PET imaging for microglia activation/monocyte infiltration, iron 
oxide particle enhanced MR imaging for phagocyte labeling, genetically engineered T-
lymphocytes for PET, as well as myelin and neuronal death PET imaging have been already 
translated and tested in humans. In addition, preclinical methods such as MPO, MMP, and 
adhesion molecule imaging have already improved our understanding of the 
pathophysiology of many neuroinflammatory diseases. In the future, distinguishing 
neurotoxic from neuroprotective leukocyte populations, identification and visualization of 
key molecules and their receptors in vivo, and imaging the targets of future therapeutics 
together with key outcome predictors such as neuronal integrity to ensure success of a 
therapeutic intervention non-invasively will likely be the next goals of molecular imaging 
research. As we continue to make progress in utilizing molecular imaging technology to 
study and understand neuroinflammation, increasing efforts and investment should be made 
to bring more of these novel imaging agents from the “bench to bedside.”
Pulli and Chen Page 20
J Clin Cell Immunol. Author manuscript; available in PMC 2014 December 16.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tAcknowledgments
Grant Support
B.P. has received a fellowship from the Ernst Schering Foundation in Berlin, Germany, and a grant from the 
National Natural Science Foundation, Beijing, China. This study was supported in part by the NIH (R01-NS070835 
and R01-NS072167 to J.W.C.).
References
1. Wang Q, Tang XN, Yenari MA. The inflammatory response in stroke. J Neuroimmunol. 2007; 
184:53–68. [PubMed: 17188755] 
2. Martino G, Adorini L, Rieckmann P, Hillert J, Kallmann B, et al. Inflammation in multiple 
sclerosis: the good, the bad, and the complex. Lancet Neurol. 2002; 1:499–509. [PubMed: 
12849335] 
3. Conti A, Gulì C, La Torre D, Tomasello C, Angileri FF, et al. Role of inflammation and oxidative 
stress mediators in gliomas. Cancers (Basel). 2010; 2:693–712. [PubMed: 24281089] 
4. Vezzani A, Granata T. Brain inflammation in epilepsy: experimental and clinical evidence. 
Epilepsia. 2005; 46:1724–1743. [PubMed: 16302852] 
5. Krstic D, Knuesel I. Deciphering the mechanism underlying late-onset Alzheimer disease. Nat Rev 
Neurol. 2013; 9:25–34. [PubMed: 23183882] 
6. Hirsch EC, Hunot S. Neuroinflammation in Parkinson’s disease: a target for neuroprotection? 
Lancet Neurol. 2009; 8:382–397. [PubMed: 19296921] 
7. Hohlfeld R, Kerschensteiner M, Meinl E. Dual role of inflammation in CNS disease. Neurology. 
2007; 68:S58–63. [PubMed: 17548571] 
8. Ekdahl CT, Kokaia Z, Lindvall O. Brain inflammation and adult neurogenesis: the dual role of 
microglia. Neuroscience. 2009; 158:1021–1029. [PubMed: 18662748] 
9. Lassmann H. Axonal injury in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2003; 74:695–697. 
[PubMed: 12754330] 
10. Rausch M, Hiestand P, Baumann D, Cannet C, Rudin M. MRI-based monitoring of inflammation 
and tissue damage in acute and chronic relapsing EAE. Magn Reson Med. 2003; 50:309–314. 
[PubMed: 12876707] 
11. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the 
leukocyte adhesion cascade updated. Nat Rev Immunol. 2007; 7:678–689. [PubMed: 17717539] 
12. Man S, Ubogu EE, Ransohoff RM. Inflammatory cell migration into the central nervous system: a 
few new twists on an old tale. Brain Pathol. 2007; 17:243–250. [PubMed: 17388955] 
13. Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev 
Drug Discov. 2005; 4:510–518. [PubMed: 15931259] 
14. McAteer MA, Sibson NR, von Zur Muhlen C, Schneider JE, Lowe AS, et al. In vivo magnetic 
resonance imaging of acute brain inflammation using microparticles of iron oxide. Nat Med. 2007; 
13:1253–1258. [PubMed: 17891147] 
15. Serres S, Soto MS, Hamilton A, McAteer MA, Carbonell WS, et al. Molecular MRI enables early 
and sensitive detection of brain metastases. Proc Natl Acad Sci U S A. 2012; 109:6674–6679. 
[PubMed: 22451897] 
16. Hoyte LC, Brooks KJ, Nagel S, Akhtar A, Chen R, et al. Molecular magnetic resonance imaging of 
acute vascular cell adhesion molecule-1 expression in a mouse model of cerebral ischemia. J 
Cereb Blood Flow Metab. 2010; 30:1178–1187. [PubMed: 20087364] 
17. Serres S, Mardiguian S, Campbell SJ, McAteer MA, Akhtar A, et al. VCAM-1-targeted magnetic 
resonance imaging reveals subclinical disease in a mouse model of multiple sclerosis. FASEB J. 
2011; 25:4415–4422. [PubMed: 21908714] 
18. Duffy BA, Choy M, Riegler J, Wells JA, Anthony DC, et al. Imaging seizure-induced 
inflammation using an antibody targeted iron oxide contrast agent. Neuroimage. 2012; 60:1149–
1155. [PubMed: 22266177] 
Pulli and Chen Page 21
J Clin Cell Immunol. Author manuscript; available in PMC 2014 December 16.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t19. Montagne A, Gauberti M, Macrez R, Jullienne A, Briens A, et al. Ultra-sensitive molecular MRI of 
cerebrovascular cell activation enables early detection of chronic central nervous system disorders. 
Neuroimage. 2012; 63:760–770. [PubMed: 22813950] 
20. Gauberti M, Montagne A, Marcos-Contreras OA, Le Behot A, Maubert E, et al. Ultra-sensitive 
molecular MRI of vascular cell adhesion molecule-1 reveals a dynamic inflammatory penumbra 
after strokes. Stroke. 2013; 44:1988–1996. [PubMed: 23743972] 
21. Kelly KA, Allport JR, Tsourkas A, Shinde-Patil VR, Josephson L, et al. Detection of vascular 
adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ Res. 2005; 96:327–
336. [PubMed: 15653572] 
22. Nahrendorf M, Jaffer FA, Kelly KA, Sosnovik DE, Aikawa E, et al. Noninvasive vascular cell 
adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. 
Circulation. 2006; 114:1504–1511. [PubMed: 17000904] 
23. Nahrendorf M, Keliher E, Panizzi P, Zhang H, Hembrador S, et al. 18F-4V for PET-CT imaging of 
VCAM-1 expression in atherosclerosis. JACC Cardiovasc Imaging. 2009; 2:1213–1222. [PubMed: 
19833312] 
24. Fu Y, Laurent S, Muller Robert N. Synthesis of a Sialyl LewisX Mimetic Conjugated with DTPA, 
Potential Ligand of New Contrast Agents for Medical Imaging. European Journal of Organic 
Chemistry. 2002; 2002:3966–3973.
25. Sibson NR, Blamire AM, Bernades-Silva M, Laurent S, Boutry S, et al. MRI detection of early 
endothelial activation in brain inflammation. Magn Reson Med. 2004; 51:248–252. [PubMed: 
14755648] 
26. Barber PA, Foniok T, Kirk D, Buchan AM, Laurent S, et al. MR molecular imaging of early 
endothelial activation in focal ischemia. Ann Neurol. 2004; 56:116–120. [PubMed: 15236408] 
27. Jin AY, Tuor UI, Rushforth D, Filfil R, Kaur J, et al. Magnetic resonance molecular imaging of 
post-stroke neuroinflammation with a P-selectin targeted iron oxide nanoparticle. Contrast Media 
Mol Imaging. 2009; 4:305–311. [PubMed: 19941323] 
28. van Kasteren SI, Campbell SJ, Serres S, Anthony DC, Sibson NR, et al. Glyconanoparticles allow 
pre-symptomatic in vivo imaging of brain disease. Proc Natl Acad Sci U S A. 2009; 106:18–23. 
[PubMed: 19106304] 
29. Serres S, Anthony DC, Jiang Y, Broom KA, Campbell SJ, et al. Systemic inflammatory response 
reactivates immune-mediated lesions in rat brain. J Neurosci. 2009; 29:4820–4828. [PubMed: 
19369550] 
30. Sipkins DA, Gijbels K, Tropper FD, Bednarski M, Li KC, et al. ICAM-1 expression in 
autoimmune encephalitis visualized using magnetic resonance imaging. J Neuroimmunol. 2000; 
104:1–9. [PubMed: 10683508] 
31. Deddens LH, van Tilborg GA, van der Toorn A, van der Marel K, Paulis LE, et al. MRI of 
ICAM-1 upregulation after stroke: the importance of choosing the appropriate target-specific 
particulate contrast agent. Mol Imaging Biol. 2013; 15:411–422. [PubMed: 23400400] 
32. Zhu Y, Ling Y, Zhong J, Liu X, Wei K, et al. Magnetic resonance imaging of radiation-induced 
brain injury using targeted microparticles of iron oxide. Acta Radiol. 2012; 53:812–819. [PubMed: 
22798291] 
33. Beer AJ, Pelisek J2, Heider P2, Saraste A3, Reeps C2, et al. PET/CT imaging of integrin αvβ3 
expression in human carotid atherosclerosis. JACC Cardiovasc Imaging. 2014; 7:178–187. 
[PubMed: 24412187] 
34. Haukkala, Johanna; Laitinen, Iina; Luoto, Pauliina; Iveson, Peter; Wilson, Ian, et al. 68Ga-DOTA-
RGD peptide: biodistribution and binding into atherosclerotic plaques in mice. Eur J Nucl Med 
Mol Imaging. 2009; 36:2058–2067. [PubMed: 19629477] 
35. Beer AJ, Schwaiger M. Imaging of integrin alphavbeta3 expression. Cancer Metastasis Rev. 2008; 
27:631–644. [PubMed: 18523730] 
36. Schmieder AH, Winter PM, Caruthers SD, Harris TD, Williams TA, et al. Molecular MR imaging 
of melanoma angiogenesis with alphanubeta3-targeted paramagnetic nanoparticles. Magn Reson 
Med. 2005; 53:621–627. [PubMed: 15723405] 
37. Zhang C, Jugold M, Woenne EC, Lammers T, Morgenstern B, et al. Specific targeting of tumor 
angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a 
Pulli and Chen Page 22
J Clin Cell Immunol. Author manuscript; available in PMC 2014 December 16.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tclinical 1.5-T magnetic resonance scanner. Cancer Res. 2007; 67:1555–1562. [PubMed: 
17308094] 
38. von Wallbrunn A, Höltke C, Zühlsdorf M, Heindel W, Schäfers M, et al. In vivo imaging of 
integrin alpha v beta 3 expression using fluorescence-mediated tomography. Eur J Nucl Med Mol 
Imaging. 2007; 34:745–754. [PubMed: 17131149] 
39. Cai W, Shin DW, Chen K, Gheysens O, Cao Q, et al. Peptide-labeled near-infrared quantum dots 
for imaging tumor vasculature in living subjects. Nano Lett. 2006; 6:669–676. [PubMed: 
16608262] 
40. Hsu AR, Hou LC, Veeravagu A, Greve JM, Vogel H, et al. In vivo near-infrared fluorescence 
imaging of integrin alphavbeta3 in an orthotopic glioblastoma model. Mol Imaging Biol. 2006; 
8:315–323. [PubMed: 17053862] 
41. Wu Y, Zhang X, Xiong Z, Cheng Z, Fisher DR, et al. microPET imaging of glioma integrin 
{alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide. J Nucl Med. 2005; 
46:1707–1718. [PubMed: 16204722] 
42. Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol. 2005; 77:598–625. [PubMed: 
15689384] 
43. Chen JW, Querol Sans M, Bogdanov A Jr, Weissleder R. Imaging of myeloperoxidase in mice by 
using novel amplifiable paramagnetic substrates. Radiology. 2006; 240:473–481. [PubMed: 
16864673] 
44. Querol M, Chen JW, Bogdanov AA Jr. A paramagnetic contrast agent with myeloperoxidase-
sensing properties. Org Biomol Chem. 2006; 4:1887–1895. [PubMed: 16688334] 
45. Chen JW, Breckwoldt MO, Aikawa E, Chiang G, Weissleder R. Myeloperoxidase-targeted 
imaging of active inflammatory lesions in murine experimental autoimmune encephalomyelitis. 
Brain. 2008; 131:1123–1133. [PubMed: 18234693] 
46. Forghani R, Wojtkiewicz GR, Zhang Y, Seeburg D, Bautz BR, et al. Demyelinating diseases: 
myeloperoxidase as an imaging biomarker and therapeutic target. Radiology. 2012; 263:451–460. 
[PubMed: 22438365] 
47. Breckwoldt MO, Chen JW, Stangenberg L, Aikawa E, Rodriguez E, et al. Tracking the 
inflammatory response in stroke in vivo by sensing the enzyme myeloperoxidase. Proc Natl Acad 
Sci U S A. 2008; 105:18584–18589. [PubMed: 19011099] 
48. Chen JW, Figueiredo JL, Wojtkiewicz GR, Siegel C, Iwamoto Y, et al. Selective factor XIIa 
inhibition attenuates silent brain ischemia: application of molecular imaging targeting coagulation 
pathway. JACC Cardiovasc Imaging. 2012; 5:1127–1138. [PubMed: 23153913] 
49. Kleijn A, Chen JW, Buhrman JS, Wojtkiewicz GR, Iwamoto Y, et al. Distinguishing inflammation 
from tumor and peritumoral edema by myeloperoxidase magnetic resonance imaging. Clin Cancer 
Res. 2011; 17:4484–4493. [PubMed: 21558403] 
50. Gross S, Gammon ST, Moss BL, Rauch D, Harding J, et al. Bioluminescence imaging of 
myeloperoxidase activity in vivo. Nat Med. 2009; 15:455–461. [PubMed: 19305414] 
51. Tseng JC, Kung AL. In vivo imaging of inflammatory phagocytes. Chem Biol. 2012; 19:1199–
1209. [PubMed: 22999887] 
52. Gan Y, Liu Q, Wu W, Yin JX, Bai XF, et al. Ischemic neurons recruit natural killer cells that 
accelerate brain infarction. Proc Natl Acad Sci U S A. 2014; 111:2704–2709. [PubMed: 
24550298] 
53. Hao J, Liu R, Piao W, Zhou Q, Vollmer TL, et al. Central nervous system (CNS)-resident natural 
killer cells suppress Th17 responses and CNS autoimmune pathology. J Exp Med. 2010; 
207:1907–1921. [PubMed: 20696699] 
54. Zhang N, Francis KP, Prakash A, Ansaldi D. Enhanced detection of myeloperoxidase activity in 
deep tissues through luminescent excitation of near-infrared nanoparticles. Nat Med. 2013; 
19:500–505. [PubMed: 23455711] 
55. Towner RA, Smith N, Saunders D, Henderson M, Downum K, et al. In vivo imaging of immuno-
spin trapped radicals with molecular magnetic resonance imaging in a diabetic mouse model. 
Diabetes. 2012; 61:2405–2413. [PubMed: 22698922] 
Pulli and Chen Page 23
J Clin Cell Immunol. Author manuscript; available in PMC 2014 December 16.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t56. Towner RA, Smith N, Saunders D, Lupu F, Silasi-Mansat R, et al. In vivo detection of free radicals 
using molecular MRI and immuno-spin trapping in a mouse model for amyotrophic lateral 
sclerosis. Free Radic Biol Med. 2013; 63:351–360. [PubMed: 23722162] 
57. Yokoyama H, Lin Y, Itoh O, Ueda Y, Nakajima A, et al. EPR imaging for in vivo analysis of the 
half-life of a nitroxide radical in the hippocampus and cerebral cortex of rats after epileptic 
seizures. Free Radic Biol Med. 1999; 27:442–448. [PubMed: 10468220] 
58. Ueda Y, Yokoyama H, Nakajima A, Takaki M, Nagatomo K, et al. In vivo EPR estimation of 
bilateral hippocampal antioxidant ability of rats with epileptogenesis induced by amygdalar FeCl3 
microinjection. Epilepsia. 2007; 48:1947–1951. [PubMed: 17559571] 
59. Yokoyama H, Itoh O, Aoyama M, Obara H, Ohya H, et al. In vivo EPR imaging by using an acyl-
protected hydroxylamine to analyze intracerebral oxidative stress in rats after epileptic seizures. 
Magn Reson Imaging. 2000; 18:875–879. [PubMed: 11027882] 
60. Fujii H1, Sato-Akaba H, Kawanishi K, Hirata H. Mapping of redox status in a brain-disease mouse 
model by three-dimensional EPR imaging. Magn Reson Med. 2011; 65:295–303. [PubMed: 
20860000] 
61. Overhauser AW. Paramagnetic Relaxation in Metals. Phy Rev. 1953; 89:689–700.
62. Yamato M, Shiba T, Yamada K, Watanabe T, Utsumi H. Noninvasive assessment of the brain 
redox status after transient middle cerebral artery occlusion using Overhauser-enhanced magnetic 
resonance imaging. J Cereb Blood Flow Metab. 2009; 29:1655–1664. [PubMed: 19553909] 
63. Yamato M, Shiba T, Naganuma T, Ichikawa K, Utsumi H, et al. Overhauser-enhanced magnetic 
resonance imaging characterization of mitochondria functional changes in the 6-hydroxydopamine 
rat model. Neurochem Int. 2011; 59:804–811. [PubMed: 21871513] 
64. Webster JM, Morton CA, Johnson BF, Yang H, Rishel MJ, et al. Functional imaging of oxidative 
stress with a novel PET imaging agent, 18F-5-fluoro-L-aminosuberic acid. J Nucl Med. 2014; 
55:657–664. [PubMed: 24578242] 
65. Van de Bittner GC, Dubikovskaya EA, Bertozzi CR, Chang CJ. In vivo imaging of hydrogen 
peroxide production in a murine tumor model with a chemoselective bioluminescent reporter. Proc 
Natl Acad Sci U S A. 2010; 107:21316–21321. [PubMed: 21115844] 
66. Wang W, Jiang X, Chen K. CePO4:Tb, Gd hollow nanospheres as peroxidase mimic and 
magnetic-fluorescent imaging agent. Chem Commun (Camb). 2012; 48:6839–6841. [PubMed: 
22648397] 
67. Lee SR, Tsuji K, Lee SR, Lo EH. Role of matrix metalloproteinases in delayed neuronal damage 
after transient global cerebral ischemia. J Neurosci. 2004; 24:671–678. [PubMed: 14736853] 
68. Zhao BQ, Wang S, Kim HY, Storrie H, Rosen BR, et al. Role of matrix metalloproteinases in 
delayed cortical responses after stroke. Nat Med. 2006; 12:441–445. [PubMed: 16565723] 
69. Weissleder R, Tung CH, Mahmood U, Bogdanov A Jr. In vivo imaging of tumors with protease-
activated near-infrared fluorescent probes. Nat Biotechnol. 1999; 17:375–378. [PubMed: 
10207887] 
70. Klohs J, Baeva N, Steinbrink J, Bourayou R, Boettcher C, et al. In vivo near-infrared fluorescence 
imaging of matrix metalloproteinase activity after cerebral ischemia. J Cereb Blood Flow Metab. 
2009; 29:1284–1292. [PubMed: 19417756] 
71. Ntziachristos V, Tung CH, Bremer C, Weissleder R. Fluorescence molecular tomography resolves 
protease activity in vivo. Nat Med. 2002; 8:757–760. [PubMed: 12091907] 
72. McCann CM, Waterman P, Figueiredo JL, Aikawa E, Weissleder R, et al. Combined magnetic 
resonance and fluorescence imaging of the living mouse brain reveals glioma response to 
chemotherapy. Neuroimage. 2009; 45:360–369. [PubMed: 19154791] 
73. Eaton VL, Vasquez KO, Goings GE, Hunter ZN, Peterson JD, et al. Optical tomographic imaging 
of near infrared imaging agents quantifies disease severity and immunomodulation of 
experimental autoimmune encephalomyelitis in vivo. J Neuroinflammation. 2013; 10:138. 
[PubMed: 24237884] 
74. Wagner S, Breyholz HJ, Höltke C, Faust A, Schober O, et al. A new 18F-labelled derivative of the 
MMP inhibitor CGS 27023A for PET: radiosynthesis and initial small-animal PET studies. Appl 
Radiat Isot. 2009; 67:606–610. [PubMed: 19167232] 
Pulli and Chen Page 24
J Clin Cell Immunol. Author manuscript; available in PMC 2014 December 16.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t75. Schäfers M, Riemann B, Kopka K, Breyholz HJ, Wagner S, et al. Scintigraphic imaging of matrix 
metalloproteinase activity in the arterial wall in vivo. Circulation. 2004; 109:2554–2559. 
[PubMed: 15123523] 
76. Kuge Y, Takai N, Ogawa Y, Temma T, Zhao Y, et al. Imaging with radiolabelled anti-membrane 
type 1 matrix metalloproteinase (MT1-MMP) antibody: potentials for characterizing 
atherosclerotic plaques. Eur J Nucl Med Mol Imaging. 2010; 37:2093–2104. [PubMed: 20625725] 
77. Sprague JE, Li WP, Liang K, Achilefu S, Anderson CJ. In vitro and in vivo investigation of matrix 
metalloproteinase expression in metastatic tumor models. Nucl Med Biol. 2006; 33:227–237. 
[PubMed: 16546677] 
78. Choi SH, Aid S, Bosetti F. The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: 
implications for translational research. Trends Pharmacol Sci. 2009; 30:174–181. [PubMed: 
19269697] 
79. Shukuri M, Takashima-Hirano M, Tokuda K, Takashima T, Matsumura K, et al. In vivo expression 
of cyclooxygenase-1 in activated microglia and macrophages during neuroinflammation visualized 
by PET with 11C-ketoprofen methyl ester. J Nucl Med. 2011; 52:1094–1101. [PubMed: 
21680698] 
80. de Vries EF, Doorduin J, Dierckx RA, van Waarde A. Evaluation of [(11)C]rofecoxib as PET 
tracer for cyclooxygenase 2 overexpression in rat models of inflammation. Nucl Med Biol. 2008; 
35:35–42. [PubMed: 18158941] 
81. de Vries EF, van Waarde A, Buursma AR, Vaalburg W. Synthesis and in vivo evaluation of 18F-
desbromo-DuP-697 as a PET tracer for cyclooxygenase-2 expression. J Nucl Med. 2003; 44:1700–
1706. [PubMed: 14530489] 
82. von Zur Muhlen C, Sibson NR, Peter K, Campbell SJ, Wilainam P, et al. A contrast agent 
recognizing activated platelets reveals murine cerebral malaria pathology undetectable by 
conventional MRI. J Clin Invest. 2008; 118:1198–1207. [PubMed: 18274670] 
83. Benavides J, Capdeville C, Dauphin F, Dubois A, Duverger D, et al. The quantification of brain 
lesions with an omega 3 site ligand: a critical analysis of animal models of cerebral ischaemia and 
neurodegeneration. Brain Res. 1990; 522:275–289. [PubMed: 2171717] 
84. Benavides J, Fage D, Carter C, Scatton B. Peripheral type benzodiazepine binding sites are a 
sensitive indirect index of neuronal damage. Brain Res. 1987; 421:167–172. [PubMed: 2891401] 
85. Raghavendra Rao VL, Dogan A, Bowen KK, Dempsey RJ. Traumatic brain injury leads to 
increased expression of peripheral-type benzodiazepine receptors, neuronal death, and activation 
of astrocytes and microglia in rat thalamus. Exp Neurol. 2000; 161:102–114. [PubMed: 10683277] 
86. Myers R, Manjil LG, Cullen BM, Price GW, Frackowiak RS, et al. Macrophage and astrocyte 
populations in relation to [3H]PK 11195 binding in rat cerebral cortex following a local ischaemic 
lesion. J Cereb Blood Flow Metab. 1991; 11:314–322. [PubMed: 1997503] 
87. Cremer JE, Hume SP, Cullen BM, Myers R, Manjil LG, et al. The distribution of radioactivity in 
brains of rats given [N-methyl-11C]PK 11195 in vivo after induction of a cortical ischaemic 
lesion. Int J Rad Appl Instrum B. 1992; 19:159–166. [PubMed: 1601669] 
88. Ramsay SC, Weiller C, Myers R, Cremer JE, Luthra SK, et al. Monitoring by PET of macrophage 
accumulation in brain after ischaemic stroke. Lancet. 1992; 339:1054–1055. [PubMed: 1349076] 
89. Venneti S, Lopresti BJ, Wang G, Hamilton RL, Mathis CA, et al. PK11195 labels activated 
microglia in Alzheimer’s disease and in vivo in a mouse model using PET. Neurobiol Aging. 
2009; 30:1217–1226. [PubMed: 18178291] 
90. Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, et al. In-vivo measurement of activated 
microglia in dementia. Lancet. 2001; 358:461–467. [PubMed: 11513911] 
91. Folkersma H, Foster Dingley JC, van Berckel BN, Rozemuller A, Boellaard R, et al. Increased 
cerebral (R)-[(11)C]PK11195 uptake and glutamate release in a rat model of traumatic brain 
injury: a longitudinal pilot study. J Neuroinflammation. 2011; 8:67. [PubMed: 21672189] 
92. Ramlackhansingh AF, Brooks DJ, Greenwood RJ, Bose SK, Turkheimer FE, et al. Inflammation 
after trauma: microglial activation and traumatic brain injury. Ann Neurol. 2011; 70:374–383. 
[PubMed: 21710619] 
Pulli and Chen Page 25
J Clin Cell Immunol. Author manuscript; available in PMC 2014 December 16.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t93. Gerhard A, Schwarz J, Myers R, Wise R, Banati RB. Evolution of microglial activation in patients 
after ischemic stroke: a [11C](R)-PK11195 PET study. Neuroimage. 2005; 24:591–595. [PubMed: 
15627603] 
94. Thiel A, Radlinska BA, Paquette C, Sidel M, Soucy JP, et al. The temporal dynamics of poststroke 
neuroinflammation: a longitudinal diffusion tensor imaging-guided PET study with 11C-PK11195 
in acute subcortical stroke. J Nucl Med. 2010; 51:1404–1412. [PubMed: 20720039] 
95. Banati RB, Newcombe J, Gunn RN, Cagnin A, Turkheimer F, et al. The peripheral benzodiazepine 
binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a 
measure of disease activity. Brain. 2000; 123:2321–2337. [PubMed: 11050032] 
96. Politis M, Giannetti P, Su P, Turkheimer F, Keihaninejad S, et al. Increased PK11195 PET binding 
in the cortex of patients with MS correlates with disability. Neurology. 2012; 79:523–530. 
[PubMed: 22764258] 
97. Debruyne JC, Versijpt J, Van Laere KJ, De Vos F, Keppens J, et al. PET visualization of microglia 
in multiple sclerosis patients using [11C]PK11195. Eur J Neurol. 2003; 10:257–264. [PubMed: 
12752399] 
98. Versijpt J, Debruyne JC, Van Laere KJ, De Vos F, Keppens J, et al. Microglial imaging with 
positron emission tomography and atrophy measurements with magnetic resonance imaging in 
multiple sclerosis: a correlative study. Mult Scler. 2005; 11:127–134. [PubMed: 15794383] 
99. Banati RB, Goerres GW, Myers R, Gunn RN, Turkheimer FE, et al. [11C](R)-PK11195 positron 
emission tomography imaging of activated microglia in vivo in Rasmussen’s encephalitis. 
Neurology. 1999; 53:2199–2203. [PubMed: 10599809] 
100. Turner MR, Cagnin A, Turkheimer FE, Miller CC, Shaw CE, et al. Evidence of widespread 
cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron 
emission tomography study. Neurobiol Dis. 2004; 15:601–619. [PubMed: 15056468] 
101. Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, et al. In vivo imaging of microglial 
activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis. 2006; 
21:404–412. [PubMed: 16182554] 
102. Imamoto N, Momosaki S, Fujita M, Omachi S, Yamato H, et al. [11C]PK11195 PET imaging of 
spinal glial activation after nerve injury in rats. Neuroimage. 2013; 79:121–128. [PubMed: 
23611861] 
103. Politis M, Pavese N, Tai YF, Kiferle L, Mason SL, et al. Microglial activation in regions related 
to cognitive function predicts disease onset in Huntington’s disease: a multimodal imaging study. 
Hum Brain Mapp. 2011; 32:258–270. [PubMed: 21229614] 
104. Shah F, Hume SP, Pike VW, Ashworth S, McDermott J. Synthesis of the enantiomers of [N-
methyl-11C]PK 11195 and comparison of their behaviours as radioligands for PK binding sites 
in rats. Nucl Med Biol. 1994; 21:573–581. [PubMed: 9234314] 
105. Petit-Taboue MC, Baron JC, Barre L, Travere JM, Speckel D, et al. Brain kinetics and specific 
binding of [11C]PK 11195 to omega 3 sites in baboons: positron emission tomography study. 
Eur J Pharmacol. 1991; 200:347–351. [PubMed: 1782994] 
106. Chauveau F, Boutin H, Van Camp N, Dollé F, Tavitian B. Nuclear imaging of 
neuroinflammation: a comprehensive review of [11C]PK11195 challengers. Eur J Nucl Med Mol 
Imaging. 2008; 35:2304–2319. [PubMed: 18828015] 
107. Van Dort ME, Ciliax BJ, Gildersleeve DL, Sherman PS, Rosenspire KC, et al. Radioiodinated 
benzodiazepines: agents for mapping glial tumors. J Med Chem. 1988; 31:2081–2086. [PubMed: 
2846836] 
108. Price GW, Ahier RG, Hume SP, Myers R, Manjil L, et al. In vivo binding to peripheral 
benzodiazepine binding sites in lesioned rat brain: comparison between [3H]PK11195 and 
[18F]PK14105 as markers for neuronal damage. J Neurochem. 1990; 55:175–185. [PubMed: 
2355218] 
109. Yanamoto K, Zhang MR, Kumata K, Hatori A, Okada M, et al. In vitro and ex vivo 
autoradiography studies on peripheral-type benzodiazepine receptor binding using 
[11C]AC-5216 in normal and kainic acid-lesioned rats. Neurosci Lett. 2007; 428:59–63. 
[PubMed: 17959307] 
Pulli and Chen Page 26
J Clin Cell Immunol. Author manuscript; available in PMC 2014 December 16.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t110. Belloli S, Moresco RM, Matarrese M, Biella G, Sanvito F, et al. Evaluation of three quinoline-
carboxamide derivatives as potential radioligands for the in vivo pet imaging of 
neurodegeneration. Neurochem Int. 2004; 44:433–440. [PubMed: 14687608] 
111. Mattner F, Katsifis A, Staykova M, Ballantyne P, Willenborg DO. Evaluation of a radiolabelled 
peripheral benzodiazepine receptor ligand in the central nervous system inflammation of 
experimental autoimmune encephalomyelitis: a possible probe for imaging multiple sclerosis. 
Eur J Nucl Med Mol Imaging. 2005; 32:557–563. [PubMed: 15875181] 
112. Mattner F, Bandin DL, Staykova M, Berghofer P, Gregoire MC, et al. Evaluation of [123I]-
CLINDE as a potent SPECT radiotracer to assess the degree of astroglia activation in cuprizone-
induced neuroinflammation. Eur J Nucl Med Mol Imaging. 2011; 38:1516–1528. [PubMed: 
21484375] 
113. Venneti S, Lopresti BJ, Wang G, Slagel SL, Mason NS, et al. A comparison of the high-affinity 
peripheral benzodiazepine receptor ligands DAA1106 and (R)-PK11195 in rat models of 
neuroinflammation: implications for PET imaging of microglial activation. J Neurochem. 2007; 
102:2118–2131. [PubMed: 17555551] 
114. Venneti S, Wagner AK, Wang G, Slagel SL, Chen X, et al. The high affinity peripheral 
benzodiazepine receptor ligand DAA1106 binds specifically to microglia in a rat model of 
traumatic brain injury: implications for PET imaging. Exp Neurol. 2007; 207:118–127. [PubMed: 
17658516] 
115. Maeda J, Ji B, Irie T, Tomiyama T, Maruyama M, et al. Longitudinal, quantitative assessment of 
amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer’s 
disease enabled by positron emission tomography. J Neurosci. 2007; 27:10957–10968. [PubMed: 
17928437] 
116. Varrone A, Mattsson P, Forsberg A, Takano A, Nag S, et al. In vivo imaging of the 18-kDa 
translocator protein (TSPO) with [18F]FEDAA1106 and PET does not show increased binding in 
Alzheimer’s disease patients. Eur J Nucl Med Mol Imaging. 2013; 40:921–931. [PubMed: 
23436070] 
117. Takano A, Piehl F, Hillert J, Varrone A, Nag S, et al. In vivo TSPO imaging in patients with 
multiple sclerosis: a brain PET study with [18F]FEDAA1106. EJNMMI Res. 2013; 3:30. 
[PubMed: 23618062] 
118. Boutin H, Chauveau F, Thominiaux C, Kuhnast B, Grégoire MC, et al. In vivo imaging of brain 
lesions with [(11)C]CLINME, a new PET radioligand of peripheral benzodiazepine receptors. 
Glia. 2007; 55:1459–1468. [PubMed: 17680643] 
119. Mattner F, Staykova M, Berghofer P, Wong HJ, Fordham S, et al. Central nervous system 
expression and PET imaging of the translocator protein in relapsing-remitting experimental 
autoimmune encephalomyelitis. J Nucl Med. 2013; 54:291–298. [PubMed: 23321458] 
120. Gulyas B, Toth M, Vas A, Shchukin E, Kostulas K, et al. Visualising neuroinflammation in post-
stroke patients: a comparative PET study with the TSPO molecular imaging biomarkers 
[11C]PK11195 and [11C]vinpocetine. Curr Radiopharm. 2012; 5:19–28. [PubMed: 22074478] 
121. Gulyás B, Tóth M, Schain M, Airaksinen A, Vas A, et al. Evolution of microglial activation in 
ischaemic core and peri-infarct regions after stroke: a PET study with the TSPO molecular 
imaging biomarker [((11))C]vinpocetine. J Neurol Sci. 2012; 320:110–117. [PubMed: 22841414] 
122. Gulyas B, Vas A, Toth M, Takano A, Varrone A, et al. Age and disease related changes in the 
translocator protein (TSPO) system in the human brain: positron emission tomography 
measurements with [11C]vinpocetine. Neuroimage. 2011; 56:1111–1121. [PubMed: 21320609] 
123. Imaizumi M, Kim HJ, Zoghbi SS, Briard E, Hong J, et al. PET imaging with [11C]PBR28 can 
localize and quantify upregulated peripheral benzodiazepine receptors associated with cerebral 
ischemia in rat. Neurosci Lett. 2007; 411:200–205. [PubMed: 17127001] 
124. Oh U, Fujita M, Ikonomidou VN, Evangelou IE, Matsuura E, et al. Translocator protein PET 
imaging for glial activation in multiple sclerosis. J Neuroimmune Pharmacol. 2011; 6:354–361. 
[PubMed: 20872081] 
125. Doorduin J, Klein HC, Dierckx RA, James M, Kassiou M, et al. [11C]-DPA-713 and [18F]-
DPA-714 as new PET tracers for TSPO: a comparison with [11C]-(R)-PK11195 in a rat model of 
herpes encephalitis. Mol Imaging Biol. 2009; 11:386–398. [PubMed: 19330384] 
Pulli and Chen Page 27
J Clin Cell Immunol. Author manuscript; available in PMC 2014 December 16.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t126. Abourbeh G, Theze B, Maroy R, Dubois A, Brulon V, et al. Imaging microglial/macrophage 
activation in spinal cords of experimental autoimmune encephalomyelitis rats by positron 
emission tomography using the mitochondrial 18 kDa translocator protein radioligand [(1)
(8)F]DPA-714. J Neurosci. 2012; 32:5728–5736. [PubMed: 22539835] 
127. Boutin H, Prenant C, Maroy R, Galea J, Greenhalgh AD, et al. [18F]DPA-714: direct comparison 
with [11C]PK11195 in a model of cerebral ischemia in rats. PLoS One. 2013; 8:e56441. 
[PubMed: 23418569] 
128. Owen DR, Gunn RN, Rabiner EA, Bennacef I, Fujita M, et al. Mixed-affinity binding in humans 
with 18-kDa translocator protein ligands. J Nucl Med. 2011; 52:24–32. [PubMed: 21149489] 
129. Carlisle SJ, Marciano-Cabral F, Staab A, Ludwick C, Cabral GA. Differential expression of the 
CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell 
activation. Int Immunopharmacol. 2002; 2:69–82. [PubMed: 11789671] 
130. Horti AG, Gao Y, Ravert HT, Finley P, Valentine H, et al. Synthesis and biodistribution of 
[11C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors 
(CB2). Bioorg Med Chem. 2010; 18:5202–5207. [PubMed: 20554448] 
131. Mu L, Bieri D, Slavik R, Drandarov K, Müller A, et al. Radiolabeling and in vitro/in vivo 
evaluation of N-(1-adamantyl)-8-methoxy-4-oxo-1-phenyl-1,4-dihydroquinoline-3-carboxamide 
as a PET probe for imaging cannabinoid type 2 receptor. J Neurochem. 2013; 126:616–624. 
[PubMed: 23795580] 
132. Vandeputte C, Casteels C, Struys T, Koole M, van Veghel D, et al. Small-animal PET imaging of 
the type 1 and type 2 cannabinoid receptors in a photothrombotic stroke model. Eur J Nucl Med 
Mol Imaging. 2012; 39:1796–1806. [PubMed: 22895861] 
133. Zhang S, Shao P, Bai M. In vivo type 2 cannabinoid receptor-targeted tumor optical imaging 
using a near infrared fluorescent probe. Bioconjug Chem. 2013; 24:1907–1916. [PubMed: 
24094147] 
134. Benito C, Romero JP, Tolón RM, Clemente D, Docagne F, et al. Cannabinoid CB1 and CB2 
receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human 
multiple sclerosis. J Neurosci. 2007; 27:2396–2402. [PubMed: 17329437] 
135. Thakur ML, Lavender JP, Arnot RN, Silvester DJ, Segal AW. Indium-111-labeled autologous 
leukocytes in man. J Nucl Med. 1977; 18:1014–1021. [PubMed: 409745] 
136. Segal AW, Arnot RN, Thakur ML, Lavender JP. Indium-111-labelled leucocytes for localisation 
of abscesses. Lancet. 1976; 2:1056–1058. [PubMed: 62903] 
137. Knochel JQ, Koehler PR, Lee TG, Welch DM. Diagnosis of abdominal abscesses with computed 
tomography, ultrasound, and 111In leukocyte scans. Radiology. 1980; 137:425–432. [PubMed: 
7433676] 
138. Peters AM, Lavender JP, Macdermot J. Diagnosing cerebral abscess with indium-111 labelled 
leucocytes. Lancet. 1980; 2:309–310. [PubMed: 6105449] 
139. Balachandran S, Husain MM, Adametz JR, Pallin JS, Angtuaco TL, et al. Uptake of indium-111-
labeled leukocytes by brain metastasis. Neurosurgery. 1987; 20:606–609. [PubMed: 3587554] 
140. Pozzilli C, Lenzi GL, Argentino C, Carolei A, Rasura M, et al. Imaging of leukocytic infiltration 
in human cerebral infarcts. Stroke. 1985; 16:251–255. [PubMed: 3975963] 
141. ten Berge RJ, Natarajan AT, Hardeman MR, van Royen EA, Schellekens PT. Labeling with 
indium-111 has detrimental effects on human lymphocytes: concise communication. J Nucl Med. 
1983; 24:615–620. [PubMed: 6864314] 
142. Thierens HM, Vral AM, Van Haelst JP, Van de Wiele C, Schelstraete KH, et al. Lymphocyte 
labeling with technetium-99m-HMPAO: a radiotoxicity study using the micronucleus assay. J 
Nucl Med. 1992; 33:1167–1174. [PubMed: 1597733] 
143. Kao CH, Wang PY, Wang YL, Chang L, Wang SJ, et al. A new prognostic index--leucocyte 
infiltration--in human cerebral infarcts by 99Tcm-HMPAO-labelled white blood cell brain 
SPECT. Nucl Med Commun. 1991; 12:1007–1012. [PubMed: 1811195] 
144. Wang PY, Kao CH, Mui MY, Wang SJ. Leukocyte infiltration in acute hemispheric ischemic 
stroke. Stroke. 1993; 24:236–240. [PubMed: 8421825] 
Pulli and Chen Page 28
J Clin Cell Immunol. Author manuscript; available in PMC 2014 December 16.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t145. Akopov SE, Simonian NA, Grigorian GS. Dynamics of polymorphonuclear leukocyte 
accumulation in acute cerebral infarction and their correlation with brain tissue damage. Stroke. 
1996; 27:1739–1743. [PubMed: 8841321] 
146. Price CJ, Menon DK, Peters AM, Ballinger JR, Barber RW, et al. Cerebral neutrophil 
recruitment, histology, and outcome in acute ischemic stroke: an imaging-based study. Stroke. 
2004; 35:1659–1664. [PubMed: 15155970] 
147. Dumarey N, Egrise D, Blocklet D, Stallenberg B, Remmelink M, et al. Imaging infection with 
18F-FDG-labeled leukocyte PET/CT: initial experience in 21 patients. J Nucl Med. 2006; 
47:625–632. [PubMed: 16595496] 
148. Bhargava KK, Gupta RK, Nichols KJ, Palestro CJ. In vitro human leukocyte labeling with 
(64)Cu: an intraindividual comparison with (111)In-oxine and (18)F-FDG. Nucl Med Biol. 2009; 
36:545–549. [PubMed: 19520295] 
149. Wunder A, Klohs J, Dirnagl U. Non-invasive visualization of CNS inflammation with nuclear and 
optical imaging. Neuroscience. 2009; 158:1161–1173. [PubMed: 18983900] 
150. Akhtar MS, Imran MB, Nadeem MA, Shahid A. Antimicrobial peptides as infection imaging 
agents: better than radiolabeled antibiotics. Int J Pept. 2012; 2012:965238. [PubMed: 22675369] 
151. Kircher MF, Gambhir SS, Grimm J. Noninvasive cell-tracking methods. Nat Rev Clin Oncol. 
2011; 8:677–688. [PubMed: 21946842] 
152. Stroh A, Zimmer C, Werner N, Gertz K, Weir K, et al. Tracking of systemically administered 
mononuclear cells in the ischemic brain by high-field magnetic resonance imaging. Neuroimage. 
2006; 33:886–897. [PubMed: 16973381] 
153. Zelivyanskaya ML, Nelson JA, Poluektova L, Uberti M, Mellon M, et al. Tracking 
superparamagnetic iron oxide labeled monocytes in brain by high-field magnetic resonance 
imaging. J Neurosci Res. 2003; 73:284–295. [PubMed: 12868062] 
154. Yeh TC, Zhang W, Ildstad ST, Ho C. Intracellular labeling of T-cells with superparamagnetic 
contrast agents. Magn Reson Med. 1993; 30:617–625. [PubMed: 8259062] 
155. Anderson SA, Shukaliak-Quandt J, Jordan EK, Arbab AS, Martin R, et al. Magnetic resonance 
imaging of labeled T-cells in a mouse model of multiple sclerosis. Ann Neurol. 2004; 55:654–
659. [PubMed: 15122705] 
156. Robinson KM, Njus JM, Phillips DA, Proctor TM, Rooney WD, et al. MR imaging of 
inflammation during myelin-specific T cell-mediated autoimmune attack in the EAE mouse 
spinal cord. Mol Imaging Biol. 2010; 12:240–249. [PubMed: 19949987] 
157. Stroh A, Zimmer C, Gutzeit C, Jakstadt M, Marschinke F, et al. Iron oxide particles for molecular 
magnetic resonance imaging cause transient oxidative stress in rat macrophages. Free Radic Biol 
Med. 2004; 36:976–984. [PubMed: 15059638] 
158. Siglienti I, Bendszus M, Kleinschnitz C, Stoll G. Cytokine profile of iron-laden macrophages: 
implications for cellular magnetic resonance imaging. J Neuroimmunol. 2006; 173:166–173. 
[PubMed: 16380168] 
159. Ferrauto G, Delli Castelli D, Terreno E, Aime S. In vivo MRI visualization of different cell 
populations labeled with PARACEST agents. Magn Reson Med. 2013; 69:1703–1711. [PubMed: 
22837028] 
160. Zimmer C, Weissleder R, Poss K, Bogdanova A, Wright SC Jr, et al. MR imaging of 
phagocytosis in experimental gliomas. Radiology. 1995; 197:533–538. [PubMed: 7480707] 
161. Murillo TP, Sandquist C, Jacobs PM, Nesbit G, Manninger S, et al. Imaging brain tumors with 
ferumoxtran-10, a nanoparticle magnetic resonance contrast agent. Therapy. 2005; 2:871–882.
162. Taschner CA, Wetzel SG, Tolnay M, Froehlich J, Merlo A, et al. Characteristics of ultrasmall 
superparamagnetic iron oxides in patients with brain tumors. AJR Am J Roentgenol. 2005; 
185:1477–1486. [PubMed: 16304001] 
163. Dousset V, Delalande C, Ballarino L, Quesson B, Seilhan D, et al. In vivo macrophage activity 
imaging in the central nervous system detected by magnetic resonance. Magn Reson Med. 1999; 
41:329–333. [PubMed: 10080281] 
164. Brochet B, Deloire MS, Touil T, Anne O, Caillé JM, et al. Early macrophage MRI of 
inflammatory lesions predicts lesion severity and disease development in relapsing EAE. 
Neuroimage. 2006; 32:266–274. [PubMed: 16650776] 
Pulli and Chen Page 29
J Clin Cell Immunol. Author manuscript; available in PMC 2014 December 16.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t165. Floris S, Blezer EL, Schreibelt G, Döpp E, van der Pol SM, et al. Blood-brain barrier permeability 
and monocyte infiltration in experimental allergic encephalomyelitis: a quantitative MRI study. 
Brain. 2004; 127:616–627. [PubMed: 14691063] 
166. Vellinga MM, Oude Engberink RD, Seewann A, Pouwels PJ, Wattjes MP, et al. Pluriformity of 
inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement. Brain. 
2008; 131:800–807. [PubMed: 18245785] 
167. Schilling M, Besselmann M, Leonhard C, Mueller M, Ringelstein EB, et al. Microglial activation 
precedes and predominates over macrophage infiltration in transient focal cerebral ischemia: a 
study in green fluorescent protein transgenic bone marrow chimeric mice. Exp Neurol. 2003; 
183:25–33. [PubMed: 12957485] 
168. Rausch M1, Baumann D, Neubacher U, Rudin M. In-vivo visualization of phagocytotic cells in 
rat brains after transient ischemia by USPIO. NMR Biomed. 2002; 15:278–283. [PubMed: 
12112610] 
169. Wiart M, Davoust N, Pialat JB, Desestret V, Moucharrafie S, et al. MRI monitoring of 
neuroinflammation in mouse focal ischemia. Stroke. 2007; 38:131–137. [PubMed: 17122417] 
170. Kim J, Kim DI, Lee SK, Kim DJ, Lee JE, et al. Imaging of the inflammatory response in 
reperfusion injury after transient cerebral ischemia in rats: correlation of superparamagnetic iron 
oxide-enhanced magnetic resonance imaging with histopathology. Acta Radiol. 2008; 49:580–
588. [PubMed: 18568546] 
171. Rausch M, Sauter A, Fröhlich J, Neubacher U, Radü EW, et al. Dynamic patterns of USPIO 
enhancement can be observed in macrophages after ischemic brain damage. Magn Reson Med. 
2001; 46:1018–1022. [PubMed: 11675656] 
172. Kleinschnitz C, Bendszus M, Frank M, Solymosi L, Toyka KV, et al. In vivo monitoring of 
macrophage infiltration in experimental ischemic brain lesions by magnetic resonance imaging. J 
Cereb Blood Flow Metab. 2003; 23:1356–1361. [PubMed: 14600443] 
173. Saleh A, Schroeter M, Jonkmanns C, Hartung HP, Mödder U, et al. In vivo MRI of brain 
inflammation in human ischaemic stroke. Brain. 2004; 127:1670–1677. [PubMed: 15128622] 
174. Nighoghossian N, Wiart M, Cakmak S, Berthezène Y, Derex L, et al. Inflammatory response after 
ischemic stroke: a USPIO-enhanced MRI study in patients. Stroke. 2007; 38:303–307. [PubMed: 
17170357] 
175. Bulte JW, de Jonge MW, de Leij L, The TH, Kamman RL, et al. Passage of DMP across a 
disrupted BBB in the context of antibody-mediated MR imaging of brain metastases. Acta 
Neurochir Suppl (Wien). 1990; 51:43–45. [PubMed: 1708649] 
176. Muldoon LL, Pagel MA, Kroll RA, Roman-Goldstein S, Jones RS, et al. A physiological barrier 
distal to the anatomic blood-brain barrier in a model of transvascular delivery. AJNR Am J 
Neuroradiol. 1999; 20:217–222. [PubMed: 10094341] 
177. Bendszus M, Stoll G. Caught in the act: in vivo mapping of macrophage infiltration in nerve 
injury by magnetic resonance imaging. J Neurosci. 2003; 23:10892–10896. [PubMed: 14645484] 
178. Oude Engberink RD, Blezer EL, Hoff EI, van der Pol SM, van der Toorn A, et al. MRI of 
monocyte infiltration in an animal model of neuroinflammation using SPIO-labeled monocytes 
or free USPIO. J Cereb Blood Flow Metab. 2008; 28:841–851. [PubMed: 18000513] 
179. Settles M, Etzrodt M, Kosanke K, Schiemann M, Zimmermann A, et al. Different capacity of 
monocyte subsets to phagocytose iron-oxide nanoparticles. PLoS One. 2011; 6:e25197. 
[PubMed: 21984904] 
180. Boven LA, Van Meurs M, Van Zwam M, Wierenga-Wolf A, Hintzen RQ, et al. Myelin-laden 
macrophages are anti-inflammatory, consistent with foam cells in multiple sclerosis. Brain. 2006; 
129:517–526. [PubMed: 16364958] 
181. Flögel U, Ding Z, Hardung H, Jander S, Reichmann G, et al. In vivo monitoring of inflammation 
after cardiac and cerebral ischemia by fluorine magnetic resonance imaging. Circulation. 2008; 
118:140–148. [PubMed: 18574049] 
182. Barkhausen J, Ebert W, Heyer C, Debatin JF, Weinmann HJ. Detection of atherosclerotic plaque 
with Gadofluorine-enhanced magnetic resonance imaging. Circulation. 2003; 108:605–609. 
[PubMed: 12835227] 
Pulli and Chen Page 30
J Clin Cell Immunol. Author manuscript; available in PMC 2014 December 16.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t183. Bendszus M, Ladewig G, Jestaedt L, Misselwitz B, Solymosi L, et al. Gadofluorine M 
enhancement allows more sensitive detection of inflammatory CNS lesions than T2-w imaging: a 
quantitative MRI study. Brain. 2008; 131:2341–2352. [PubMed: 18669504] 
184. Henning TD, Saborowski O, Golovko D, Boddington S, Bauer JS, et al. Cell labeling with the 
positive MR contrast agent Gadofluorine M. Eur Radiol. 2007; 17:1226–1234. [PubMed: 
17206428] 
185. Kipper SL, Rypins EB, Evans DG, Thakur ML, Smith TD, et al. Neutrophil-specific 99mTc-
labeled anti-CD15 monoclonal antibody imaging for diagnosis of equivocal appendicitis. J Nucl 
Med. 2000; 41:449–455. [PubMed: 10716317] 
186. Thakur ML, Marcus CS, Henneman P, Butler J, Sinow R, et al. Imaging inflammatory diseases 
with neutrophil-specific technetium-99m-labeled monoclonal antibody anti-SSEA-1. J Nucl Med. 
1996; 37:1789–1795. [PubMed: 8917176] 
187. Becker W, Bair J, Behr T, Repp R, Streckenbach H, et al. Detection of soft-tissue infections and 
osteomyelitis using a technetium-99m-labeled anti-granulocyte monoclonal antibody fragment. J 
Nucl Med. 1994; 35:1436–1443. [PubMed: 8071688] 
188. Becker W, Borst U, Fischbach W, Pasurka B, Schäfer R, et al. Kinetic data of in-vivo labeled 
granulocytes in humans with a murine Tc-99m-labelled monoclonal antibody. Eur J Nucl Med. 
1989; 15:361–366. [PubMed: 2776795] 
189. Li Y, Ye D. Molecular biology for formyl peptide receptors in human diseases. J Mol Med (Berl). 
2013; 91:781–789. [PubMed: 23404331] 
190. Babich JW, Tompkins RG, Graham W, Barrow SA, Fischman AJ. Localization of radiolabeled 
chemotactic peptide at focal sites of Escherichia coli infection in rabbits: evidence for a receptor-
specific mechanism. J Nucl Med. 1997; 38:1316–1322. [PubMed: 9255175] 
191. Fischman AJ, Pike MC, Kroon D, Fucello AJ, Rexinger D, et al. Imaging focal sites of bacterial 
infection in rats with indium-111-labeled chemotactic peptide analogs. J Nucl Med. 1991; 
32:483–491. [PubMed: 2005457] 
192. Locke LW, Chordia MD, Zhang Y, Kundu B, Kennedy D, et al. A novel neutrophil-specific PET 
imaging agent: cFLFLFK-PEG-64Cu. J Nucl Med. 2009; 50:790–797. [PubMed: 19372473] 
193. Stasiuk GJ, Smith H, Wylezinska-Arridge M, Tremoleda JL, Trigg W, et al. Gd3+ cFLFLFK 
conjugate for MRI: a targeted contrast agent for FPR1 in inflammation. Chem Commun (Camb). 
2013; 49:564–566. [PubMed: 23208551] 
194. Xiao L, Zhang Y, Liu Z, Yang M, Pu L, et al. Synthesis of the Cyanine 7 labeled neutrophil-
specific agents for noninvasive near infrared fluorescence imaging. Bioorg Med Chem Lett. 
2010; 20:3515–3517. [PubMed: 20488705] 
195. Zhang Y, Xiao L, Chordia MD, Locke LW, Williams MB, et al. Neutrophil targeting 
heterobivalent SPECT imaging probe: cFLFLF-PEG-TKPPR-99mTc. Bioconjug Chem. 2010; 
21:1788–1793. [PubMed: 20843030] 
196. Gross MD, Shapiro B, Fig LM, Steventon R, Skinner RW, et al. Imaging of human infection with 
(131)I-labeled recombinant human interleukin-8. J Nucl Med. 2001; 42:1656–1659. [PubMed: 
11696635] 
197. Moyer BR, Vallabhajosula S, Lister-James J, Bush LR, Cyr JE, et al. Technetium-99m-white 
blood cell-specific imaging agent developed from platelet factor 4 to detect infection. J Nucl 
Med. 1996; 37:673–679. [PubMed: 8691265] 
198. Marcus C, Thakur ML, Huynh TV, Louie JS, Leibling M, et al. Imaging rheumatic joint diseases 
with anti-T lymphocyte antibody OKT-3. Nucl Med Commun. 1994; 15:824–830. [PubMed: 
7838446] 
199. Kinne RW, Becker W, Schwab J, Horneff G, Schwarz A, et al. Comparison of 99Tcm-labelled 
specific murine anti-CD4 monoclonal antibodies and nonspecific human immunoglobulin for 
imaging inflamed joints in rheumatoid arthritis. Nucl Med Commun. 1993; 14:667–675. 
[PubMed: 8371892] 
200. Barrera P, van der Laken CJ, Boerman OC, Oyen WJ, van de Ven MT, et al. Radiolabelled 
interleukin-1 receptor antagonist for detection of synovitis in patients with rheumatoid arthritis. 
Rheumatology (Oxford). 2000; 39:870–874. [PubMed: 10952741] 
Pulli and Chen Page 31
J Clin Cell Immunol. Author manuscript; available in PMC 2014 December 16.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t201. Signore A, Picarelli A, Annovazzi A, Britton KE, Grossman AB, et al. 123I-Interleukin-2: 
biochemical characterization and in vivo use for imaging autoimmune diseases. Nucl Med 
Commun. 2003; 24:305–316. [PubMed: 12612472] 
202. Signore A, Chianelli M, Annovazzi A, Bonanno E, Spagnoli LG, et al. 123I-interleukin-2 
scintigraphy for in vivo assessment of intestinal mononuclear cell infiltration in Crohn’s disease. 
J Nucl Med. 2000; 41:242–249. [PubMed: 10688106] 
203. Di Gialleonardo V, Signore A, Glaudemans AW, Dierckx RA, De Vries EF. N-(4-18F-
fluorobenzoyl)interleukin-2 for PET of human-activated T lymphocytes. J Nucl Med. 2012; 
53:679–686. [PubMed: 22499614] 
204. Berger C, Gremlich HU, Schmidt P, Cannet C, Kneuer R, et al. In vivo monitoring the fate of 
Cy5.5-Tat labeled T lymphocytes by quantitative near-infrared fluorescence imaging during 
acute brain inflammation in a rat model of experimental autoimmune encephalomyelitis. J 
Immunol Methods. 2007; 323:65–77. [PubMed: 17433359] 
205. Costa GL, Sandora MR, Nakajima A, Nguyen EV, Taylor-Edwards C, et al. Adoptive 
immunotherapy of experimental autoimmune encephalomyelitis via T cell delivery of the IL-12 
p40 subunit. J Immunol. 2001; 167:2379–2387. [PubMed: 11490028] 
206. Yaghoubi SS, Jensen MC, Satyamurthy N, Budhiraja S, Paik D, et al. Noninvasive detection of 
therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma. Nat Clin Pract Oncol. 
2009; 6:53–58. [PubMed: 19015650] 
207. Malviya G, Anzola KL, Podestà E, Laganà B, Del Mastro C, et al. (99m)Tc-labeled rituximab for 
imaging B lymphocyte infiltration in inflammatory autoimmune disease patients. Mol Imaging 
Biol. 2012; 14:637–646. [PubMed: 22127469] 
208. Vervoordeldonk SF, Heikens J, Goedemans WT, Merle PA, von dem Borne AE, et al. 99mTc-
CD19 monoclonal antibody is not useful for imaging of B cell non-Hodgkin’s lymphoma. Cancer 
Immunol Immunother. 1996; 42:291–296. [PubMed: 8706051] 
209. Lamonica D, Czuczman M, Nabi H, Klippenstein D, Grossman Z. Radioimmunoscintigraphy 
(RIS) with bectumomab (Tc99m labeled IMMU-LL2, Lymphoscan) in the assessment of 
recurrent non-Hodgkin’s lymphoma (NHL). Cancer Biother Radiopharm. 2002; 17:689–697. 
[PubMed: 12537673] 
210. Put S, Schoonooghe S, Devoogdt N, Schurgers E, Avau A, et al. SPECT imaging of joint 
inflammation with Nanobodies targeting the macrophage mannose receptor in a mouse model for 
rheumatoid arthritis. J Nucl Med. 2013; 54:807–814. [PubMed: 23447654] 
211. Zhou J, Hao G, Weng H, Tsai YT, Baker DW, et al. In vivo evaluation of medical device-
associated inflammation using a macrophage-specific positron emission tomography (PET) 
imaging probe. Bioorg Med Chem Lett. 2013; 23:2044–2047. [PubMed: 23481649] 
212. Blankenberg FG, Tait JF, Blankenberg TA, Post AM, Strauss HW. Imaging macrophages and the 
apoptosis of granulocytes in a rodent model of subacute and chronic abscesses with radiolabeled 
monocyte chemotactic peptide-1 and annexin V. Eur J Nucl Med. 2001; 28:1384–1393. 
[PubMed: 11585299] 
213. Hartung D, Petrov A, Haider N, Fujimoto S, Blankenberg F, et al. Radiolabeled Monocyte 
Chemotactic Protein 1 for the detection of inflammation in experimental atherosclerosis. J Nucl 
Med. 2007; 48:1816–1821. [PubMed: 17942805] 
214. Klohs J, Gräfe M, Graf K, Steinbrink J, Dietrich T, et al. In vivo imaging of the inflammatory 
receptor CD40 after cerebral ischemia using a fluorescent antibody. Stroke. 2008; 39:2845–2852. 
[PubMed: 18635859] 
215. Barkhof F. Imaging of remyelination. Mult Scler. 1997; 3:129–132. [PubMed: 9291166] 
216. Barkovich AJ. Magnetic resonance techniques in the assessment of myelin and myelination. J 
Inherit Metab Dis. 2005; 28:311–343. [PubMed: 15868466] 
217. Stankoff B, Wang Y, Bottlaender M, Aigrot MS, Dolle F, et al. Imaging of CNS myelin by 
positron-emission tomography. Proc Natl Acad Sci U S A. 2006; 103:9304–9309. [PubMed: 
16754874] 
218. Wang Y, Wu C, Caprariello AV, Somoza E, Zhu W, et al. In vivo quantification of myelin 
changes in the vertebrate nervous system. J Neurosci. 2009; 29:14663–14669. [PubMed: 
19923299] 
Pulli and Chen Page 32
J Clin Cell Immunol. Author manuscript; available in PMC 2014 December 16.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t219. Wu C, Wei J, Tian D, Feng Y, Miller RH, et al. Molecular probes for imaging myelinated white 
matter in CNS. J Med Chem. 2008; 51:6682–6688. [PubMed: 18844339] 
220. Wu C, Wang C, Popescu DC, Zhu W, Somoza EA, et al. A novel PET marker for in vivo 
quantification of myelination. Bioorg Med Chem. 2010; 18:8592–8599. [PubMed: 21071233] 
221. Wu C, Zhu J, Baeslack J, Zaremba A, Hecker J, et al. Longitudinal positron emission tomography 
imaging for monitoring myelin repair in the spinal cord. Ann Neurol. 2013; 74:688–698. 
[PubMed: 23818306] 
222. de Paula Faria D, de Vries EF, Sijbesma JW, Dierckx RA, Buchpiguel CA, et al. PET imaging of 
demyelination and remyelination in the cuprizone mouse model for multiple sclerosis: a 
comparison between [11C]CIC and [11C]MeDAS. Neuroimage. 2014; 87:395–402. [PubMed: 
24188813] 
223. Wang C, Wu C, Popescu DC, Zhu J, Macklin WB, et al. Longitudinal near-infrared imaging of 
myelination. J Neurosci. 2011; 31:2382–2390. [PubMed: 21325505] 
224. Frullano L, Wang C, Miller RH, Wang Y. A myelin-specific contrast agent for magnetic 
resonance imaging of myelination. J Am Chem Soc. 2011; 133:1611–1613. [PubMed: 21265506] 
225. Frullano L, Zhu J, Wang C, Wu C, Miller RH, et al. Myelin imaging compound (MIC) enhanced 
magnetic resonance imaging of myelination. J Med Chem. 2012; 55:94–105. [PubMed: 
22098543] 
226. Frullano L, Zhu J, Miller RH, Wang Y. Synthesis and characterization of a novel gadolinium-
based contrast agent for magnetic resonance imaging of myelination. J Med Chem. 2013; 
56:1629–1640. [PubMed: 23311333] 
227. Stankoff B, Freeman L, Aigrot MS, Chardain A, Dolle F, et al. Imaging central nervous system 
myelin by positron emission tomography in multiple sclerosis using [methyl-(1)(1)C]-2-(4′-
methylaminophenyl)- 6-hydroxybenzothiazole. Ann Neurol. 2011; 69:673–680. [PubMed: 
21337603] 
228. Tallantyre EC, Bø L, Al-Rawashdeh O, Owens T, Polman CH, et al. Clinico-pathological 
evidence that axonal loss underlies disability in progressive multiple sclerosis. Mult Scler. 2010; 
16:406–411. [PubMed: 20215480] 
229. Bjartmar C, Kidd G, Mörk S, Rudick R, Trapp BD. Neurological disability correlates with spinal 
cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann 
Neurol. 2000; 48:893–901. [PubMed: 11117546] 
230. Saver JL. Time is brain--quantified. Stroke. 2006; 37:263–266. [PubMed: 16339467] 
231. Sette G, Baron JC, Young AR, Miyazawa H, Tillet I, et al. In vivo mapping of brain 
benzodiazepine receptor changes by positron emission tomography after focal ischemia in the 
anesthetized baboon. Stroke. 1993; 24:2046–2057. [PubMed: 8248987] 
232. Heiss WD, Graf R, Fujita T, Ohta K, Bauer B, et al. Early detection of irreversibly damaged 
ischemic tissue by flumazenil positron emission tomography in cats. Stroke. 1997; 28:2045–
2051. [PubMed: 9341717] 
233. Pascual B, Prieto E, Arbizu J, Marti-Climent JM, Peñuelas I, et al. Decreased carbon-11-
flumazenil binding in early Alzheimer’s disease. Brain. 2012; 135:2817–2825. [PubMed: 
22961552] 
234. Juhász C, Nagy F, Watson C, da Silva EA, Muzik O, et al. Glucose and [11C]flumazenil positron 
emission tomography abnormalities of thalamic nuclei in temporal lobe epilepsy. Neurology. 
1999; 53:2037–2045. [PubMed: 10599778] 
235. Rojas S, Martin A, Pareto D, Herance JR, Abad S, et al. Positron emission tomography with 11C-
flumazenil in the rat shows preservation of binding sites during the acute phase after 2 h-transient 
focal ischemia. Neuroscience. 2011; 182:208–216. [PubMed: 21402129] 
236. Bouvard S, Costes N, Bonnefoi F, Lavenne F, Mauguière F, et al. Seizure-related short-term 
plasticity of benzodiazepine receptors in partial epilepsy: a [11C]flumazenil-PET study. Brain. 
2005; 128:1330–1343. [PubMed: 15758035] 
237. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, et al. Annexin V for flow 
cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 
1994; 84:1415–1420. [PubMed: 8068938] 
Pulli and Chen Page 33
J Clin Cell Immunol. Author manuscript; available in PMC 2014 December 16.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t238. Blankenberg FG, Katsikis PD, Tait JF, Davis RE, Naumovski L, et al. In vivo detection and 
imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci U S 
A. 1998; 95:6349–6354. [PubMed: 9600968] 
239. Narula J, Acio ER, Narula N, Samuels LE, Fyfe B, et al. Annexin-V imaging for noninvasive 
detection of cardiac allograft rejection. Nat Med. 2001; 7:1347–1352. [PubMed: 11726976] 
240. Lorberboym M, Blankenberg FG, Sadeh M, Lampl Y. In vivo imaging of apoptosis in patients 
with acute stroke: correlation with blood-brain barrier permeability. Brain Res. 2006; 1103:13–
19. [PubMed: 16806116] 
241. Lampl Y, Lorberboym M, Blankenberg FG, Sadeh M, Gilad R. Annexin V SPECT imaging of 
phosphatidylserine expression in patients with dementia. Neurology. 2006; 66:1253–1254. 
[PubMed: 16636246] 
242. Bahmani P, Schellenberger E, Klohs J, Steinbrink J, Cordell R, et al. Visualization of cell death in 
mice with focal cerebral ischemia using fluorescent annexin A5, propidium iodide, and TUNEL 
staining. J Cereb Blood Flow Metab. 2011; 31:1311–1320. [PubMed: 21245871] 
243. Schellenberger EA, Bogdanov A Jr, Hogemann D, Tait J, Weissleder R, et al. Annexin V-CLIO: 
a nanoparticle for detecting apoptosis by MRI. Mol Imaging. 2002; 1:102–107. [PubMed: 
12920851] 
244. Yagle KJ, Eary JF, Tait JF, Grierson JR, Link JM, et al. Evaluation of 18F-annexin V as a PET 
imaging agent in an animal model of apoptosis. J Nucl Med. 2005; 46:658–666. [PubMed: 
15809489] 
245. Lawson VA, Haigh CL, Roberts B, Kenche VB, Klemm HM, et al. Near-infrared fluorescence 
imaging of apoptotic neuronal cell death in a live animal model of prion disease. ACS Chem 
Neurosci. 2010; 1:720–727. [PubMed: 22778809] 
246. Reshef A, Shirvan A, Shohami E, Grimberg H, Levin G, et al. Targeting cell death in vivo in 
experimental traumatic brain injury by a novel molecular probe. J Neurotrauma. 2008; 25:569–
580. [PubMed: 18447626] 
247. Reshef A, Shirvan A, Grimberg H, Levin G, Cohen A, et al. Novel molecular imaging of cell 
death in experimental cerebral stroke. Brain Res. 2007; 1144:156–164. [PubMed: 17328873] 
248. Reshef A, Shirvan A, Waterhouse RN, Grimberg H, Levin G, et al. Molecular imaging of 
neurovascular cell death in experimental cerebral stroke by PET. J Nucl Med. 2008; 49:1520–
1528. [PubMed: 18703595] 
249. Zhang X, Paule MG, Newport GD, Sadovova N, Berridge MS, et al. MicroPET imaging of 
ketamine-induced neuronal apoptosis with radiolabeled DFNSH. J Neural Transm. 2011; 
118:203–211. [PubMed: 20963452] 
250. Xie BW, Park D, Van Beek ER, Blankevoort V, Orabi Y, et al. Optical imaging of cell death in 
traumatic brain injury using a heat shock protein-90 alkylator. Cell Death Dis. 2013; 4:e473. 
[PubMed: 23348587] 
Pulli and Chen Page 34
J Clin Cell Immunol. Author manuscript; available in PMC 2014 December 16.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tFigure 1. 
Targets and probes in molecular imaging of neuroinflammation. Key cellular players in 
neuroinflammation are activated microglia, monocytes/macrophages, neutrophils, T-
lymphocytes and B-lymphocytes. Microglia are resident brain leukocytes, and upregulate 
translocator protein (TSPO), cyclooxygenase 1 (COX1), and cannabinoid receptor 2 (CB2) 
under inflammatory conditions. Blood-borne leukocytes extravasate into the brain through 
interaction of cell surface integrins with specific endothelial adhesion molecules (e.g., 
ICAM-1, VCAM-1, P-/E-selectin). Once in the subendothelial space, exposure to 
chemokines (e.g. CCL2 released by microglia) further directs them towards their target. 
Stimulated cells then secrete effector molecules (e.g., matrix metalloproteinases [MMPs] 
and myeloperoxidase [MPO]), which trigger axonal damage and/or demyelination. Cell 
interaction between antigen-presenting cells (APCs, e.g., B-lymphocytes, microglia, 
dendritic cells) is mediated via CD40 amongst other molecules. Activated platelets can also 
produce reactive oxidative species and trigger thrombosis. BL: Bioluminescence imaging; 
FL: Fluorescence Imaging (Adapted from Servier Medical Art).
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Molecular imaging targets and probes to visualize damage caused by neuroinflammation. 
Neuronal damage and demyelination are hallmarks of neuroinflammation. Injured neurons 
express phophatidylserine, which can be targeted by annexin-V. Caspases are key mediators 
of neuronal apoptosis, while Aposense agents enter dying cells that have lost integrity of 
their membranes. GABAa-receptor expression has been established as a marker for neuronal 
integrity. The myelin sheath around axons is electrically insulating and allows for fast signal 
transmission. Several different agents have been demonstrated to specifically bind to myelin, 
thus allowing for assessment of demyelination in neuroinflammation. FL: Fluorescence 
imaging (Adapted from Servier Medical Art).
Pulli and Chen Page 36
J Clin Cell Immunol. Author manuscript; available in PMC 2014 December 16.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tFigure 3. 
MR Imaging of adhesion molecules in neuroinflammation. (A) VCAM-MPIO compared to 
IgG-MPIO enhanced MR imaging after intracerebral injection of IL-1β, axial T2*-weighted 
images and 3-dimensional volumetric maps of VCAM-MPIO (or IgG-MPIO) binding are 
shown. (B) VCAM-upregulation after intracerebral injection of TNF on histology and 
VCAM-MPIO-enhanced MRI. (C) Diffuse VCAM upregulation in the brain of an EAE 
mouse on VCAM-MPIO-enhanced MRI. (D) 3D reconstruction maps of GNP-sLex- and 
control GNP-enhanced MRI in EAE mice reveal increased selectin expression in the 
inflamed brain. (Modified from McAteer etl al. [14], Montagne et al. [19], and Serres et al. 
[29] with permission).
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Molecular MR imaging of myeloperoxidase. (A) MPO-Gd enhanced MRI in EAE, where 
more lesions (arrows) are detected with MPO-Gd compared to DTPA-Gd. In addition, 
delayed enhancement confirms MPO-mediated activation. (B) MPO-Gd enhanced MRI in 
glioma shows low MPO activity before oncolytic virus administration (day 0). On days 1 
and 3, MPO-Gd contrast increased in the peritumor area but is still present in the tumor 
center. On day 7, most of the enhancement in the center fades, but persistent MPO-Gd 
enhancement in seen in the periphery. (C) MPO-Gd enhanced MRI on day 3 after stroke 
correlates well with infarct on H&E staining on histology, where MPO immunostaining is 
present. (Modified from Chen et al. [45], Breckwoldt et al. [49], and Kleijn et al. [47] with 
permission.)
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MMP imaging in neuroinflammation (A) Combined FMT and MR imaging of brain tumors 
with Prosense demonstrates focal activity of protease activity associated with gliomas. 
Prosense signal correlated well with tumor size on MRI. (B) In vivo fluorescence imaging at 
24 hours after MCAO in mice, where strong fluorescence was detected over the infarcted 
hemisphere. In contradistinction, very little signal increase was seen with MMPsense in 
sham mice or with control probe in stroke mice [70]. (C) Ex vivo correlation of Prosense 
signal (Cy5.5 channel) with TTC staining, and with BBB breakdown (FITC-albumin) in 
stroke mice. (Modified from McCann et al. [72] and Klohs et al. [70] with permission.).
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TSPO PET imaging in neuroinflammation. (A) 11C-PK11195 PET in patients with 
Alzheimer’s disease shows increased uptake suggestive of microglia activation in the 
entorhinal, temporoparietal and cingulate cortex. (B) 11C-PK11195 PET in a patient with 
acute ischemic stroke. Coregistered T1-weighted MRI and PET demonstrated 11C-PK11195 
enhancement surrounding the infarct seen on MRI on day 5, while considerable overlap 
between MRI and PET was found on day 13. (C) Chronic microglia activation following 
TBI as evaluated by 11C-PK11195 PET, where increased uptake in the thalami of all TBI 
subjects is seen compared to control individuals. (D) In a patient with MS, focally increased 
uptake of the TSPO PET agent 11C-PBR28 is seen in gadolinium enhancing and FLAIR 
hyperintense MRI lesions (arrows). (Modified from Cagnin et al. [90] Gerhard et al. [93], 
Ramlackhansingh et al. [92], and Oh et al. [124] with permission.)
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Cell tracking strategies. (A) Noncontrast CT in acute ischemic stroke and SPECT of in vitro
111In-troponolate-labeled neutrophils demonstrate cell infiltration into the infarcted brain 
region. (B) In vivo and ex vivo MR imaging of iron oxide labeled T-lymphocytes in EAE 
mice, and corresponding histological evidence of demyelination (H&E and luxol fast blue 
staining). (C) MBP-specific CD4+ T-lymphocytes were transduced with a GFP-luciferase 
retroviral vector and transferred into naïve or MBP-immunized EAE mice. On 
bioluminescence imaging, cells localized at the immunization sites as well as the brain in a 
clinically symptomatic mouse but not in a naïve control mouse. (D) MRI and PET of a 
patient with glioma injected with genetically targeted autologous cytolytic CD8+ T 
lymphocytes to express the IL-13 zetakine gene and herpes simplex virus 1 thymidine kinase 
suicide gene, which allows for PET detection using the radiotracer 18F-FHBG. (Modified 
from Price et al. [146], Anderson et al. [155], Costa et al. [205] and Yaghoubi et al. [206] 
with permission).
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Imaging of phagocytic cells with iron oxide-enhanced MR imaging. (A) USPIO and DOTA-
Gd-enhanced MR imaging of EAE rats. A periventricular lesion shows DOTA-Gd 
enhancement but not USPIO uptake. Vice versa, a ventral lesion shows USPIO uptake but 
no DOTA-Gd enhancement. No enhancement is seen in a control animal. (B) Pre-Gd T2 
MRI on a MS patient demonstrates multiple lesions, and while there is a DTPA-Gd and 
USPIO enhancing lesions (arrow), there also is an USPIO-uptake-only lesion (arrowhead). 
(C) Spatiotemporal profile of USPIO uptake in the ischemic rat brain over 7 days. While 
USPIO uptake is first seen in the periphery of the infarct (ADC map), uptake becomes more 
central on the following days, while no uptake is seen on day 7. (D) Comparison of USPIO 
and DTPA-Gd in a patient with ischemic stroke. Diffusion-weighted imaging displays 
ischemic area. Areas of USPIO uptake are clearly different from gadolinium enhancement. 
(Modified from Rausch et al. [10,171], Vellinga et al. [166] and Saleh et al. [173] with 
permission.)
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Molecular imaging of demyelination. (A) In vitro MeDas staining of myelin sheaths in the 
corpus callosum and comparison with Black Gold staining. (B) 3D PET and CT fusion 
image of a rat after injection of 11C-MeDas demonstrates decreased tracer uptake in the 
thoracic spinal cord in EAE versus preimmunized state. (C) PET-MR fusion imaging of 
demyelination with 11C-PIB in a patient with MS. MS plaques (arrows) and grey matter 
(arrowheads) sow decreased tracer uptake, suggesting reduced myelin content. (D) Optical 
near-infrared in vivo imaging of demyelination using the fluorescent compound DBT. In the 
cuprizone model of demyelination, reduced DBT uptake was detected compared to control 
mice. (Modified from Wu et al. [220,221], Stankoff et al. [227], and Wang et al. [223] with 
permission.)
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Molecular imaging of neuronal death. (A) PET-MR fusion imaging of a patient with 
Alzheimer’s disease using 11C-flumazenil. Regions with decreased tracer binding are shown 
in red on brain surface images, and yellow-red on axial images, and correspond to regions 
with greatest degree of neuronal loss in neuropathological studies. (B) In vivo and ex vivo 
near-infrared fluorescence annexin A5 imaging of ischemic stroke mice. Strong fluorescence 
is seen over the ischemic hemisphere only after injection of active Cy5.5-annexin A5. (C) In 
vivo and ex vivo imaging of mice with TBI using GSAO-AF750 or a nonspecific control 
probe. Specific uptake is seen in the damaged brain region. (D) PET using 18F-ML-10 to 
detect cell death in stroke mice in vivo demonstrates tracer uptake in the ischemic 
hemisphere. (Modified from Pascual et al. [233], Bahmani et al. [242], Xie et al. [250] and 
Reshef et al. [248] with permission.)
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